Topic index

 

A detailed list of topics on follicular lymphoma is covered here:

–> diagnostic  and  treatment  information  including  information  on  new  drugs.

–> natural  strategies  targeted  to  follicular  lymphoma  linking  lifestyle  to  optimal  genetic  expression.

Upon  completion of the registration process and becoming a member you will have access to the material listed here.

Items in red are considered highest priority.

 

  A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

 

A

Acid/Alkaline Myth, Article #3, p.67; June 2008 Newsletter, p. 14; June 2007 Newsletter, p. 13-14

AHCC, December 2014 Newsletter, p. 11

Alcohol

  • Research on alcohol consumption and incidence of lymphoma, October 2014 Newsletter, p. 24-26; November 2013 Newsletter, p. 9-11

AMPK

  • Epigenetic upregulation of AMPK through use of the targeted natural strategies, Article #10, 17-19; Article #11, p. 6-7
  • AMPK and protein Myc, Article #11, p.14
  • Enzyme AMPK helps restrict lymphoma cell growth, Article #10, p. 19-19: February 2013 Newsletter, p. 10-12

Amino Acids

  • Adequate, balanced intake of all 9 essential amino acids vital for healthy immunity, January 2015 Newsletter, p. 17-18; December 2013 Newsletter, p. 7-12
  • Methionine and its critical role in methylation, May 2014 Newsletter, p. 8-10
  • Blood test for amino acids, Article #7, p.41-42; Article #5, p. 27-28
  • March 2010 Newsletter, p. 11-15, August 2010 Newsletter, p. 18-19

Angiogenesis

  • Anti-angiogenic epigenetic effects of ellagic acid, Article #10, p.25-26; Article #11, p. 6; May 2016 Newsletter, p. 15-20
  • Angiogenesis and ellagic acid, Article #10, p. 25-26: November 2010 Newsletter, p.9, September 2010 Newsletter, p. 8-9; Article #3, p. 44
  • Web link to video of Dr. William Li discussing the importance of using natural strategies to block angiogenesis and tumor development, November 2010 Newsletter, p. 9

Antioxidants , August 2014 Newsletter, p. 15; March 2013 Newsletter, p. 13-15; Article #3, p. 66-68; Article #7, p. 13-17

Anti-CD20 Monoclonal Antibodies (mAbs), January 2008 Newsletter, p. 16-17; December 2004 Newsletter, p. 6-7

A.P. John Clinic, March 2010 Newsletter, p.13

Apples, February2013 Newsletter, p. 13-14; Article #3, p.52; December 2015 Newsletter, p.11-12: September 2011 Newsletter, p.22

Aspartame (Nutrasweet)

  • Potentially harmful epigenetic effects of aspartame, Article #10, p. 26-27; Article #11, p.6, January 2015 Newsletter, p. 15-17
  • Study finds association between aspartame intake in diet sodas and incidence of NHL, December 2012 Newsletter, p. 15-16; Article #3 p.36,51

Aspirin, November 2016 Newsletter, p. 15

Avocado, October 2007 Newsletter, p. 12-13; June 2007 Newsletter, p. 4-5

Astaxanthin, June 2012 Newsletter, p. 23; July 2011 Newsletter, p. 12-13, June 2011 Newsletter, p.22

[ return to top ]

_________________________________________

B

B Symptoms and Transformation, Article #4, p. 5-6; Article #3, p. 71-72; Article #2, p. 34

Balance, Article #3, p. 38-40; November 2005 Newsletter, p. 2-4

Bananas, Article #3, p. 52-53

BCCA (British Columbia Cancer Agency)

  • Drs. Connors, Gascoyne and Marra’s genomic research on lymphoma, August 2014 Newsletter, p. 29

bcl-2 Gene, July 2010 Newsletter, p. 18-19

Beets, July 2016 Newsletter, p. 19-20

Bendamustine (Treanda)

  • Analysis of GADOLIN clinical trial results which compared Bendamustine to Gazyva-Bendamustine combo, May 2016 Newsletter, p. 4-6
  • Treatment options in the event of relapse after treatment with R-Benda, October 2015 Newsletter, p. 13-19
  • Review of 2012 study comparing bendamustine to other treatment options, Article # 7 p. 18-20; December 2012 Newsletter, p. 13-14
  • General information, Article #6, p.15-16; August 2012 Newsletter, p. 6-7; May 2006 Newsletter, p. 8-10, December 2004
  • Comparative data for R-Bendamustine and R-CHOP as choice for initial treatment, Article # 7, p. 27; August 2011 Newsletter, p. 11-14; February 2011 Newsletter, p. 14-17
  • Results of 2009 NCI clinical trial, December 2009 Newsletter, “Bendamustine Better Than CHOP?”, p. 15-17

Benzene

  • Benzene, and products containing it (petrochemical products and solvents), is a toxic exposure risk for fNHL survivors, May 2017 Newsletter, p. 9-10

Berries

  • Berries as part of targeted natural strategies breakfast, Article #3, p. 49; April 2011 Newsletter, p. 18-22
  • NF Kappa B pathway, October 2009. p. 16-17
  • Blackberries and their effect on gene expression, September 2008 Newsletter, p. 4
  • Test tube study finds compounds found in berries kill cancer cells, May 2008 Newsletter, p. 11-12

Bexxar

  • General information, Article #6 , p. 24-25; “Bexxar Bye Bye”, September 2013 Newsletter, p. 21-13; August 2012 Newsletter, p. 19-20; June 2007 Newsletter, “Before, After and New Research”, p. 11-13; February 2005 Newsletter, “Bexxar in Balance”, p. 4-6
  • Research comparing Zevalin and Bexxar, July 2008 Newsletter, p. 13-14
  • Research evaluating effectiveness, June 2010 Newsletter, p. 12-13

Biomarkers

  • High tumor microenvironment expression of CD7 and dietary lifestyle factors in follicular lymphoma patients linked to increased survival time, December 2012 Newsletter, p. 8-10
  • Prognostic significance of key biomarkers in pathology reports, Article #5, p. 15-17
  • Biomarkers predicting overall survival time and transformation, March 2011 Newsletter, p. 10-12; September 2008 Newsletter, p. 5-6; November 2006 Newsletter, p. 4-5

Bisphenol A (BPA)

  • BPA overactivates gene EZH2 creating adverse epigenetic impacts for follicular lymphoma survivors, May 2017 Newsletter, p. 12-14; January 2016 Newsletter, p. 2-8; September 2016 Newsletter, p.5

Bitter Melon

  • Epigenetic anti-cancer effects of bitter melon, Article #11, p.5-6
  • August 2013 Newsletter, p. 28-29; April 2013 Newsletter, p. 8-9; Article #3, p. 58

Blood Tests

  • Essential information on standard blood tests for fNHL patients, Article #5, p. 20-25; February 2012 Newsletter, p. 21-24
  • Lymphocyte and hemoglobin readings in blood tests, October 2014 Newsletter, p. 5-12
  • How diet can affect blood tests results, Article #7, p. 39-41
  • Non-standard blood tests useful for fNHL patients, Article #5. p. 25-28
  • Why WBC results need to be supplemented with tests for immunoglobulin levels, May 2013 Newsletter, p. 11-13
  • FBG (fasting blood glucose) test, October 2014 Newsletter, p. 13-15; March 2014 Newsletter, p. 19; Article #7, p. 44-45

Bone marrow transplants (allogeneic), January 2005 Newsletter, p. 6-8

Bowel Concerns,  April 2017 Newsletter, p. 7-12; October 2016 Newsletter, p. 4-13; Article #7, p. 45-47; August 2014 Newsletter, p. 24-25; June 2014 Newsletter, p. 17-20; February 2013 Newsletter, p. 16-17; June 2011 Newsletter, p. 13-18, August 2010 Newsletter, p. 13-17

Breakfast (jump start your TNS day), Article #3, p. 47-50; December 2015 Newsletter, p. 9-10;  January 2015 Newsletter, p. 23-24

Broccoli , April 2012 Newsletter, p. 11-14; Article #3, p.48-49; April 2015 Newsletter, p. 16-17; July 2011 Newsletter, p. 11-12, May 2011 Newsletter, p. 10-13

Brown Rice, Article #3, p.56

Brussels sprouts, July 2011 Newsletter, p. 11-12, May 2011 Newsletter, p. 10-13, November 2010 Newsletter, p. 8-9, Article #3, p. 48-49

Budwig diet, August 2006 Newsletter, p. 3-5

Bulky Tumors, Article #6, p. 9

[ return to top ]

________________________________________________

C

Cannabinoids,  January 2017 Newsletter, p. 11-14

Carrageenan, May 2014 Newsletter, p. 7-8

Carbohydrates

  • “You Asked About Bread”, November 2014 Newsletter, p. 9-10
  • Potentially cancer-promoting epigenetic effects of a high carbohydrate diet, Article #10, p. 22-24; Article #11, p. 10-11, February 2015 Newsletter, p. 20-21
  • Dietary suggestions for fNHL patients regarding daily carbohydrate intake, May 2013 Newsletter, p. 13-15

CD4 and CD8 Biomarkers-CD4/CD8 Ratio, March 2010 Newsletter, p. 3-4; February 2010 Newsletter, p. 3-6

Cell (genetic) signaling pathways and cancer, Article #10, p. 9-12; May 2011 Newsletter, p. 4-6, June 2008 Newsletter, p. 3-5

Celiac disease

  • February 2009 Newsletter, p. 11-12; April 2008 Newsletter, p. 11-12

Chemotherapy and Optimization Strategies

  • Failure to follow chemo optimization strategies in Article #8 is a strategic error in the management of follicular lymphoma, July 2015 Newsletter, p. 21-22
  • Exercise during chemotherapy, Article #8, p 6&13, Article #9, p. 8-9; November 2016 Newsletter, p. 4-5; November 2014 Newsletter, p. 14-16
  • Chemotherapies used to combat transformation, Article #4, p.8-12
  • “New Drug Reduces Chemo Side-Effects”, September 2016 Newsletter, p. 22-23
  • Effectiveness of chemotherapy in mice enhanced by healthy gut bacteria, December 2013 Newsletter, p. 18-19
  • Probiotics and chemotherapy, Article #11, p. 12
  • “When Chemotherapy Really Shines”, September 2010 Newsletter, p. 3-6
  • Dietary and lifestyle strategies during chemo”, Article #8; April 2010 Newsletter, p. 6-13
  • Dietary and lifestyle strategies recovering from chemo, Article #9, April 2010 Newsletter, p. 13-16
  • Suggested routine on days of chemo treatment, Article #8, p. 6-8
  • Hyperthermia/ Hot Baths during chemotherapy, Article #8, p. 3-8; Article #7, p. 25-26
  • General daily guidelines while in chemo treatment cycle, Article #9, p. 8-9
  • American Cancer Society 2011 research study on fish oil and chemotherapy showed dramatically increased response rates and overall survival time (compared with patients not taking fish oil) for NON-small cell lung cancer patients, April 2011 Newsletter, p. 15-17
  • Chemotherapy optimization strategies, Article #8,; August 2007 Newsletter, p. 2-5
  • Chemotherapy and Vitamin D, Article #8, p. 5-6
  • Brisk walk on day of chemotherapy, Article #8, p. 6
  • Fish oil supplementation during chemotherapy, Article #8, p.9-10; Article #11, p. 12
  • Vitamin supplementation during chemotherapy, Article #8, p. 8-12
  • Supplements to avoid during chemotherapy, Article #8, p. 12
  • What to do to get the best response during CHOP, Article #8
  • Ginger used to combat nausea during chemotherapy, June 2009 Newsletter, p. 18

Cheson, Dr. Bruce

  • Commentary on maintenance rituximab from a prominent lymphoma specialist, January 2014 Newsletter, p. 17-18; September 2012 Newsletter, p. 4-6

Chlorambucil (Leukeran)

  • “Doctors Using Chlorambucil to Treat Follicular Lymphoma”, October 2014 Newsletter, p. 22-24
  • “New Research Shows Outstanding Results with Chlorambucil”, August 2014 Newsletter, p. 4-7
  • “Chlorambucil … Still a Good Option”, April 2014 Newsletter, p. 15-18
  • Lymphoma Survival members stories of success, December 2016 Newsletter, p. 16-17
  • General information, Article #6, p.13-14.; August 2012 Newsletter, p. 8-9; Article #7, p. 17-18
  • Chlorambucil and stem cell transplants, April 2007 Newsletter, p. 6
  • Research on highly effective outcomes for using chlorambucil in the treatment of mantle cell lymphoma, April 2011 Newsletter, p. 14-15, January 2011 Newsletter, p. 14-15
  • Why so little use?, Article #6, p.35-43
  • Excellent clinical results( best current info. and update), January 2010 Newsletter, p. 4-6
  • Additional clinical results, September 2009 Newsletter, p. 11-13
  • Updated protocol for “pulsing mode”, August 2010 Newsletter, p. 20
  • Chlorambucil, the non-sexy wonder drug (with extensive references), November 2008 Newsletter, p. 2-7
  • Chlorambucil and rituximab, June 2007 Newsletter, p. 9-10

Chronic Hidden Infection

  • Association between infection and first location of nodes, February 2014 Newsletter, p. 13-17
  • April 2013 Newsletter, p. 12-17; Article #3, p. 59-64; March 2008 Newsletter, p. 10-12; November 2005 Newsletter, p. 4-7

Cinnamon

  • Epigenetic anti-cancer effects of cinnamon, Article #11, p.6
  • August 2013 Newsletter, p. 28-29; April 2013 Newsletter, p. 7-8

Clinical Remission

  • “Sustained Clinical Remissions: Toward a Two-Step Program”, April 2017 Newsletter, p. 4-7

Clinical Trials

  • “Cancer Drugs Approved Too Rapidly — Expert Review”, June 2016 Newsletter, p. 4-6
  • Clinical trials for follicular lymphoma, December 2013 Newsletter, p. 23
  • Pros and cons of participation in clinical trials, Article #7, p. 31-34

CLA , December 2015 Newsletter, p. 19-20; March 2015 Newsletter, p. 17-18; Article #3, p.54

CLL (Chronic Lymphocytic Leukemia) , December 2013 Newsletter, p. 23

Colostrum

  • “Colostrum May Help with Compromised Immunity and Chemo Damage”, April 2017 Newsletter, p. 13-17
  •  Article #3, p. 63; Article #7, p. 29; December 2010 Newsletter, p. 18, April 2010 Newsletter, p.6

CoEnzyme Q-10, September 2015 Newsletter, p. 24-26; October 2010 Newsletter, p. 21, Article #8, p.10-11; March 2009 Newsletter, p. 10; Article #3, p.58

Coleman, Dr. Morton

  • Commentary on maintenance rituximab from a prominent lymphoma specialist, September 2012 Newsletter, p. 5

Consultation Guidelines

  • February 2011 Newsletter, p. 19; July 2009 Newsletter, p. 17-18; also click on “Phone Consultation” tab on the top left area of this webpage
  • Frequently asked questions about scans that arise in phone consultations, June 2015 Newsletter, p. 18-19
  • “Should I Choose Treatment or Try the “Natural” Route?”, February 2014 Newsletter, p. 13-17

Cosmetic Concerns, Article #6, p. 11-12; Article #7, p. 35-36

CPOP, Article #6, p.28; January 2005 Newsletter, p. 8

Cranberry Juice, Article #3, p.51

CRISPR, October 2016 Newsletter, p. 14-15; December 2016 Newsletter, p. 25-26

CT Scans (see Scans)

Curcumin

  • “Curcumin to Reduce Inflammation”, March 2017 Newsletter, p. 9-10
  • “Newly identified Benefit of Curcumin”, November 2014 Newsletter, p. 16-19; Article #3, p. 58
  • Curcumin may help stimulate FOXP3+ Treg production in the bowel, June 2017 Newsletter, p. 14-15
  • Epigenetic benefits of turmeric and curcumin, Article #11, p.17-18
  • Deception in labeling and supplement buyer guidelines, June 2011 Newsletter, p. 23-24, March 2011 Newsletter, p. 21
  • Downregulation of gene CXCR4 and curcumin, April 2007 Newsletter, p. 3
  • Bioavailability of curcumin, October 2016 Newsletter, p. 20-21; September 2015 Newsletter, p. 22-24; November 2010 Newsletter, p. 16-17, October 2009 Newsletter, p. 20; August 2008 Newsletter, p. 5-7; August 2007 Newsletter, p. 10-12
  • Curcumin and bowel inflammation, October 2016 Newsletter, p. 7-8; September 2015 Newsletter, p. 22-24
  • Curcumin absorption and need to add to a fat, October 2006 Newsletter, p. 12-14
  • Green tea extract effectiveness and curcumin, November 2007 Newsletter, p. 7-8; July 2007 Newsletter, p. 5
  • Curcumin and cancer — research studies
    • Possible effect on apoptosis (programmed cell death), May 2009 Newsletter, p. 7-8
    • Research on fNHL and curcumin, April 2007 Newsletter, p.3; October 2006 Newsletter, p. 2-3; August 2006 Newsletter, p. 6-7

Cure

  • Durable cure for fNHL not possible without correction of the underlying genetics, December 2015 Newsletter, p. 3-7;  March 2014 Newsletter, p. 9-10; June 2012 Newsletter, p. 3-8
  • Definition of cure compared with remission, April 2009 Newsletter, p. 6-8

Cyclophosphamide (Cy), Article #6, p.17; August 2012 Newsletter, p. 11; August 2011 Newsletter, p. 14-16

 

[return to top ]

______________________________________

D

Dairy Products, June 2016 Newsletter, p. 13-15; April 2015 Newsletter, p. 21-23

DCA, Article #6, p. 30-31; August 2012 Newsletter, p. 11-12; June 2011 Newsletter, p. 11-13, November 2010 Newsletter, p. 13, July 2010 Newsletter, p. 14: June 2010 Newsletter, p. 7-9, February 2007 Newsletter, p. 2 , March 2007 Newsletter, p.3, April 2007 Newsletter, p.2-3, September 2008 Newsletter, p.6-8

Dental Problems and fNHL, June 2015 Newsletter, p. 14-15; April 2013 Newsletter, p. 14; Article #7, p. 6-7; Article #3, p. 61

Depression, April 2010 Newsletter, p. 16-18

Devil’s Claw, November 2009 Newsletter, p. 18

Diagnosis

  • “New Developments in Diagnosing Follicular Lymphoma”, December 2014 Newsletter, p. 12-15
  • Determining stage and grade and the time of diagnosis, Article #5, p. 6-8
  • Problems associated with diagnosing transformation, Article #4, p. 6-8
  • General diagnosis information, Article #5, p. 4-14; Article #2, p. 9-13, 31-34; September 2005 Newsletter, p. 2-3.
  • Obtaining the correct diagnosis, Article #5, p. 8-9; November 2010 Newsletter, p. 4-5
  • Common sub-groups of patients at time of initial diagnosis, Article #5, p. 4-6; November 2010 Newsletter, p. 5-6
  • Lack of concurrence in diagnosis, Article #5, p. 8; September 2005 Newsletter, p. 2-3
  • Circulating tumor DNA test (ctDNA), Article #2, p. 30
  • Biopsies and diagnosis, Article #5, p. 8-9
  • Composite histology, Article #5, p.8-9; September 2008 Newsletter, p. 11-12; October 2007 Newsletter, p. 7-8
  • Discordant histology, Article #5, p.9; September 2008 Newsletter, p. 11-12; October 2007 Newsletter, p. 7-8
  • Low and high tumor burden at the time of diagnosis, Article #5, p. 9-10
  • Risks of deferring treatment at the time of diagnosis, Article #5, p. 12-14
  • Important biomarkers in pathology reports at the time of diagnosis, Article #5, p. 15-17
  • Bone marrow biopsies, Article #5, p.9
  • Variable pathology within and between nodes complicates diagnosis and treatment decisions, December 2013 Newsletter, p. 12-14
  • FOXP3 biomarker as breakthrough in predicting survival and transformation, December 2009 Newsletter, p. 11-13
  • CD4 and CD8 Biomarkers-CD4/CD8 Ratio as prognostic indicators for long term survival, February 2010 Newsletter, p. 3-6

Double-Hit Lymphoma , September 2014 Newsletter, p. 9-11

DNA Repair Genes

  • Description of DNA repair genes and their importance for holding fNHL in check, August 2015 Newsletter, p. 12

Drug Development (New)

  • “Cancer Drugs Approved Too Rapidly — Expert Review”, June 2016 Newsletter, p. 4-6
  • “New Drugs:  Careful Assessment Required”, January 2016 Newsletter, p. 9-10
  • “T-Cell Immunotherapy: Promising or Playing with Fire?”,  February 2017 Newsletter, p. 11-13
  • “Improvements to Rituximab — No NOT GAZYVA Obinutuzumab”,  November 2016 Newsletter, p. 13-14
  • Trial results with new kinase drugs Imbruvica and Idelalisib with relapsed indolent or follicular lymphoma, January 2014 Newsletter, p. 12-16
  • The rising cost of new cancer drugs creates “financial toxicity” for follicular lymphoma survivors, November 2015 Newsletter, p. 12-15
  • “The Cancer Industry is Going Through a Re-make”, April 2015 Newsletter, p. 11-14
  • The fundamental dilemma faced by the new genetic-based drugs, October 2014 Newsletter, p. 17-21
  • Ibrutinib clinical trials with follicular lymphoma, September 2013 Newsletter, p. 3-13
  • List and discussion of new drugs under development for fNHL, Article #6, p. 28-34; July 2013 Newsletter, p. 17-19

Dynamic Observation

  • “Watch and Wait: Maintenance Rituximab … Latest Expert Opinions”, November 2011 Newsletter, p. 2-5
  • As a viable option for pro-active, newly diagnosed patients, May 2009 Newsletter, p. 14-15
  • How to monitor progress during periods of dynamic observation, Article #7. p. 8-11
  • Risks of deferring treatment at the time of diagnosis, Article #5, p. 12-14
  • Using lifestyle strategies during periods of dynamic observation, July 2008 Newsletter, p. 3-6
  • Comparison of dynamic observation as a choice for managing low-risk prostate cancer vs. low-risk fNHL, January 2011 Newsletter, p. 17-18
  • Watch and wait: My friends don’t understand, September 2006 Newsletter, p. 5-7
  • Watch and wait before and between treatments, January 2005 Newsletter, p. 4-6

[ return to top ]

_____________________________________________

E

Eggs, Article #3, p. 49; February 2010 Newsletter, p.15, August 2010 Newsletter, p.19, September 2010 Newsletter, p. 19

Ellagic Acid

  • Epigenetic anti-cancer effects of ellagic acid, Article #10, p. 25-26; Article #11, p. 6; October 2016 Newsletter, p. 13
  • Ellagic acid may block blood vessel formation in tumors, Article #10, p. 25-26; Article #3, p. 49
  • Daily juice drinks essential for therapeutic dose of ellagic acid, Article #3, p. 56
  • In raspberries, cranberries, pomegranate juice, walnuts and strawberries, Article #3, p. 49 & 51; July 2006 Newsletter, p. 5
  • Ellagic acid’s role in preventing angiogenesis, Article #10, p. 25-26; November 2010 Newsletter, p. 9, September 2010 Newsletter, p. 8-9
  • Ellagic acid helps to regulate methylation process, February 2011 Newsletter, p. 5-6

Environmental Toxins

  • “Toxic Exposures and Non-Hodgkins Lymphoma”,  May 2017 Newsletter, p. 4-15
  • “Counteracting Cancer-Causing Toxins with Natural Strategies”, September 2016 Newsletter, p. 4-12
  • Roundup weedkiller (glyphosate) linked with follicular lymphoma, May 2015 Newsletter, p. 16-19
  • Bisphenol A (BPA) is linked to overexpression of gene EZH2, a key epigenetic driver of follicular lymphoma, January 2016 Newsletter, p. 7-8
  • “Artificial Turf Fields Linked to Lymphoma”, April 2016 Newsletter, p. 10-12
  • Cancer-promoting environmental toxins associated with follicular lymphoma, Article #11, p. 6-7

Epigenetics

  • Article #11: “Epigenetic Regulators of Follicular Lymphoma: A Reference Guide”, linking the latest in cancer-related epigenetic research to key anti-cancer lifestyle strategies
  • Article #10: “Getting Follicular Lymphoma Cells to Die on Their Own”, detailed examination of new epigenetic research applied to follicular lymphoma
  • Article #3 — Why epigenetics is the basis for the 4P-GRS program, p. 7-12
  • Links to videos explaining epigenetics, Article #3,  p. 13-14
  • “How Healthy Normal Cells Defeat Follicular Lymphoma”, February 2017 Newsletter, p.  4-8
  • “Normal Cells Cure Cancer”, July 2016 Newsletter, p. 3-10
  • The epigenome as a “wildcard” in the management of follicular lymphoma, November 2015 Newsletter, p. 7-8
  • “A Closer Look at Preventing New Tumors”,  May 2016 Newsletter, p. 15-20
  • Epigenetic Age Predicts Cancer”, March 2016 Newsletter, p.24
  • Detailed table listing the epigenetic gene remediation properties of individual strategies in the 4P-GRS program, October 2015 Newsletter, p. 22-23
  • DNA repair genes and tumor suppressor genes are our “friends” and oncogenes are our “enemies”, and the epigenome mediates between them, February 2016 Newsletter, p. 7-13
  • “Cancer 2015 … A New Era Unfolds”, July 2015 Newsletter, p. 5-10
  • Diagram depicting role of lifestyle, the epigenome and the genome as interrelated factors in cancer progression and regression, August 2015 Newsletter, p. 14-15
  • Epigenetics and natural regression of follicular lymphoma, Article #11, p. 21-22
  • “Emotional Well Being Linked to Gene Expression”, April 2016 Newsletter, p. 15-17
  • Medical experts explain the power of epigenetics in two important videos, February 2015 Newsletter, p. 11
  • The Roadmap Epigenomics Program, March 2015 Newsletter, p. 6-8
  • “Sugar, Glutamine, and Cancer Genes”, April 2013 Newsletter, p. 3-7
  • Concerns with genetic-based drugs for follicular lymphoma targeting single genes, September 2013 Newsletter, p. 3-13
  • Ringleader fNHL genes and enzymes and lifestyle strategies affecting their epigenetic expression, February 2013 Newsletter, p. 2-15
  • Why current breakthrough research in the “new cancer paradigm” is not resulting in patients receiving widely used new cancer treatments, October 2012 Newsletter, p. 3-9
  • How the new science of epigenetics can create more durability (e.g. sustained success in holding fNHL in check), Article #10; Article #11; June 2012 Newsletter, p. 3-8; May 2012 Newsletter, p. 8-9 ; Article #3, p.7-13
  • “New Drug Innovation Focuses on Cancer as a Multi-Step Process”, May 2012 Newsletter, p. 3-5
  • “Latest (Practical) Genetic Research … New Directions with New Strategies for Our Success”, April 2012 Newsletter, p. 7-11
  • The importance of epigenetic intervention in treating fNHL, October 2011 Newsletter, p. 3-7
  • “Significant New Direction in Cancer Research”, July 2011 Newsletter, p. 1-11
  • “The “How to” Details for Lengthening Your Life — Getting into the Thrive Zone with Epigenetics”, May 2011 Newsletter, p. 2-24
  • “Makings of a Miracle”, April 2011 Newsletter, p. 3-7
  • Comparison of the two key approaches (drug development vs. diet and lifestyle strategies) to managing and preventing cancer through epigenetic processes, January 2011 Newsletter, p. 9-12
  • How TNS (targeted natural strategies) work to effect epigenetic processes in the body by targeting anti-cancer cell signaling pathways, Article #10, Article #11; Article #3, p. 7-14
  • Epigenetics researcher Dr. Dean Ornish finds major shifts in gene expression in cancer patients participating in a 3 month program of lifestyle changes, Article #10, p. 4-6; July 2008 Newsletter, p. 3-6
  • “Let the Cancer Cells Die On Their Own”, July 2010 Newsletter, p. 10-13

Emulsifiers,  January 2017 Newsletter, p. 23

Endocrine Disruptors, Article #3, p.64

Exercise

  • Exercise during chemotherapy, Article #8 p.6 &13,; Article #9, p. 8-9; November 2014 Newsletter, p. 14-16
  • Epigenetic anti-cancer effects of exercise, Article #10, p. 16-19; Article #11, p. 7-8;  Article #7, p.36-38; March 2015 Newsletter, p. 15-16
  • “The Daily Double: Where the Gold is Buried”, April 2012 Newsletter, p. 3-6
  • How exercise can purify the lymph fluid, May 2014 Newsletter, p. 6-7; Article #7, p. 37-38
  • Enzyme AMPK, generated through exercise, found to restrict lymphoma cell growth, Article #10, p. 17-19; Article #11, p.8-9; February 2013 Newsletter, p. 10-12, Article #3, p. 28
  • Exercise-sugar-glutamine-insulin connection, February 2012 Newsletter, p. 3-8
  • 17 hour magic strategy (Daily Double), Article #3, p. 25-32; October 2012 Newsletter, p. 12-14; September 2012 Newsletter, p. 12-14; May 2012 Newsletter, p. 10-11; March 2012 Newsletter, p. 4-6; February 2012 Newsletter, p. 8-10
  • Research shows exercise is an important strategy for reducing risk of cancer recurrence, Article #10, p. 16-19; October 2012 Newsletter, p. 12-13
  • The importance of daily movement to lymphatic system health, January 2013 Newsletter, p.9-11; September 2012 Newsletter, p. 14-15
  • Long walks and hikes may contribute to increasing levels of oxygen in the blood, healthy sweat and lymph purification, and slowing cancer growth rates, September 2014 Newsletter, p. 17-19; Article #10, p. 8-10; January 2014 Newsletter, p. 10-12; July 2013 Newsletter, p. 7-15; May 2013 Newsletter, p. 19-20
  • Exercise as an important natural strategy, Article #7, p. 31-32; September 2011 Newsletter, p. 14-15; Article #3, p. 25-32; July 2015 Newsletter, p.12-17
  • Physical activity associated with higher overall survival in cancer patients,  May 2017 Newsletter, p. 17-19
  • Exercise — 7 facts with more benefits than you think, January 2010 Newsletter, p. 6-9
  • Exercise for lymphoma patients — trial results, October 2009 Newsletter, p. 11-12
  • Optimal time of day for exercise, November 2011 Newsletter, p. 17-18
  • ” Exercise: Providing Four Essential Benefits”, May 2010 Newsletter, p. 5-7
  • Endorphins and exercise, March 2010 Newsletter, p. 17
  • Evening exercise, March 2010 Newsletter, p. 17
  • Research on cancer and exercise
    • Study finds that light, regular exercise positively effects the expression of over 7000 genes, September 2013 Newsletter, p. 18
    • Video clip on cancer research and exercise, June 2012 Newsletter, p. 8
    • Beneficial results of aerobic exercise, October 2009 Newsletter, p. 11-13
    • High muscle strength and cancer mortality, July 2009 Newsletter, p. 16
    • Various research studies on exercise and cancer, February 2008 Newsletter, p. 7-10
    • Large study on physical activity and lymphoma, September 2007 Newsletter, p. 9-10
    • Exercise and its effect on immunity, March 2005 Newsletter, p. 11-13

Exosomes, September 2014 Newsletter, p. 13-14

Extra-Nodal Lymphomas, May 2012 Newsletter, p. 13-14

EZH2 (gene)  

  • Gene EZH2 , a key epigenetic regulator of follicular lymphoma, overactivated when exposed to bisphenol A (BPA), January 2016 Newsletter, p. 4-6; September 2016 Newsletter, p.5
  • Natural strategies to “tame” the overexpression of EZH2, December 2016 Newsletter, p. 7-8:  January 2016 Newsletter, p. 7-8
  • Gene EZH2 identified as one of the 7 most important genes in the m7-FLIPI  research published in 2015, September 2015 Newsletter p. 4-6; 10-14.

[ return to top ]

__________________________________________________

F

Fasting Strategy, December 2012 Newsletter, p. 3-6; November 2012 Newsletter, p. 6-7 and p. 14-15

Fats

  • “Why Good Fats are Extra Important to Combat Follicular Lymphoma”, December 2015 Newsletter, p. 20-21;  March 2017 Newsletter, p. 7-8; November 2014 Newsletter, p. 10-13

Flavonoids, May 2009 Newsletter, p. 8-10; June 2008 Newsletter, p. 6

Fiber, October 2016 Newsletter, p. 10-11, March 2017 Newsletter, p. 11-13; December 2016 Newsletter, p. 23-24

Fish Oil

  • Epigenetic anti-cancer effects of fish oil (wild salmon oil), September 2015 Newsletter, p. 21-22; Article #11, p. 11-12
  • American Cancer Society 2011 research study on fish oil and chemotherapy showed dramatically increased response rates and overall survival time (compared with patients not taking fish oil) for NON-small cell lung cancer patients, April 2011 Newsletter, p. 15-17
  • Supplementation during chemotherapy, Article #8, p. 9-10
  • Wild Salmon Oil, Article #3, p. 58

FLIPI score

  • FLIPI and FLIPI 2, strengths and weaknesses as prognostic assessment tool, Article #2, p. 29-31
  • “FLIPI: How Valid?” , June 2014 Newsletter, p. 8-11
  • FLIPI score at the time of diagnosis, Article #5, p.10-12
  • m7-FLIPI as a potentially new and better forecasting tool, September 2015 Newsletter, p. 4-6; 10-14; Article #2, p. 33
  • Limitations of FLIPI for predicting survival, December 2009 Newsletter, p. 11-13

Fludarabine

  • Study shows R-Fludarabine regimen unsafe and not recommended for an upfront therapy for fNHL, November 2011 Newsletter, p. 11-13
  • “Major Caution re Fludarabine”, November 2010 Newsletter, p. 12-13
  • General information, Article #6, p. 16-17, August 2012 Newsletter, p. 12-13
  • Fludarabine with CPOP, Article #6, p.28
  • Combining with Rituximab (R-FND), Article #6, p. 16-17
  • Possible impact on future stem cell transplants (SCTs), Article #6, p. 16-17

Follicular Lymphoma

  • “Toxic Exposures and Non-Hodgkins Lymphoma”,  May 2017 Newsletter, p. 4-15
  • “Risk Factors Associated with Follicular Lymphoma”, March 2017 Newsletter, p. 3-7
  • “The Development and Resolution of Follicular Lymphoma”, January 2017 Newsletter, p. 3-4
  • “Follicular Lymphoma 2016: A Rapidly Shifting Landscape”, January 2016 Newsletter, p. 17-20
  • “How Healthy Normal Cells Defeat Follicular Lymphoma”, February 2017 Newsletter, p.  4-8
  •  Winning the follicular lymphoma challenge  — the need to understand the “genetic fact” , December 2015 Newsletter, p. 3-7
  •  “Which is worse, enlarged nodes or new nodes?”, September 2015 Newsletter, p. 17-20
  • “The Development and Resolution of Follicular Lymphoma”, June 2015 Newsletter, p. 5-8
  • “Beating Follicular Lymphoma is a Two-Step Process”, March 2015 Newsletter, p. 4-6 
  • “New Developments in Diagnosing Follicular Lymphoma”, December 2014 Newsletter, p. 12-15
  • “20+ Strategic Errors in Managing Follicular Lymphoma”, December 2014 Newsletter, p. 4-11
  • “OK Doc, Why Did I Get Follicular Lymphoma?”, November 2014 Newsletter, p. 6-9
  • “Why Nodes Grow and Why They Shrink”, March 2013 Newsletter, p. 2-6
  • “Purify my Lymph Fluid”, May 2014 Newsletter, p. 6-7
  • High and low risk categorization for fNHL patients with m7-FLIPI, September 2015 Newsletter, p. 7-9
  • How to measure progress with fNHL, Article #7, p. 8-11; June 2012 Newsletter, p. 9-13
  • The stages of progress in regression and resolution of fNHL, August 2015 Newsletter, p. 16-18
  • Why follicular lymphoma cells are more susceptible to dying on their own as compared to other types of malignant cells, Article #10, p. 7
  • “The Way Ahead … The Research We Really Need”, February 2013 Newsletter, p. 17-20
  • Research outlook … “the big picture”, July 2013 Newsletter, p. 24-28
  • “Bad luck”, good fortune, and the origins of follicular lymphoma, February 2015 Newsletter, p. 4-9
  • New paradigm for managing follicular lymphoma, Article #2, p. 4-6
  • Follicular lymphoma in young adults, June 2014 Newsletter, p. 11-12
  • “Does Follicular Lymphoma Spread to Other Organs?”, May 2013 Newsletter, p. 11
  • “The Seven Premises in Understanding and Managing fNHL”, November 2010 Newsletter, p. 3-12
  • Web link to “Follicular Lymphoma Revisited” (Dr. Saul Rosenberg reviews 25 years of fNHL research), March 2008 Newsletter, p.6
  • When to treat, Article #6 p. 5-13; October 2012 Newsletter, p. 9-11
  • Incidence rates, Article #2, p. 23-25
  • Explaining predicted survival and survival statistics, Article #2, p.25-29
  • The development and progression of follicular lymphoma (overview), Article #2, p 4-8; .October 2008 Newsletter, p. 2-7
  • “What is an appropriate fNHL Checkup?”, February 2011 Newsletter, p. 17-19
  • Dietary factors and fNHL incidence, September 2009 Newsletter, p. 8-10
  • Funding for fundamental research for fNHL, July 2008 Newsletter, p. 17-19; October 2006 Newsletter, p. 8-12
  • Stanford research on overall survival (OS) , Article #2, p. 26-29; December 2007 Newsletter, p. 5-7; May 2005 Newsletter, p. 7-10
  • Seasonal variance in the incidence of fNHL, July 2007 Newsletter, p. 14-15
  • Web link to Dr. Cheson webcast presenting an overview of follicular lymphoma, July 2007 newsletter, p. 10
  • Follicular Lymphoma: An 80 year perspective, May 2007 Newsletter, p. 10-11

Foods to Avoid

  • Need for fNHL patients to avoid whey protein powder, glutamine supplements, and protein powder supplements, Article #7, p. 43-44; December 2012 Newsletter, p. 12-13; Article #3, p. 55; June 2012 Newsletter, p. 17-19
  • Need for fNHL patients to avoid supplementation with glutamine, Article #11, p. 9-10; November 2012 Newsletter, p. 9-10
  • Milk and its pro-inflammatory properties, June 2016 Newsletter, p. 13-15
  • Pitfalls of flour, sugar and bread for cancer survivors, November 2013 Newsletter, p. 11-13
  • List of foods to avoid, Article #3, p. 55 &59

Four Pillar Approach

  • Prioritizing the four pillars, Article #10, p. 15-18; Article #3, p. 16; May 2012 Newsletter, p. 11-13

FOXP3 Biomarker

  • FOXP3, a potent prognostic indicator of long-term survival with fNHL, increases dramatically with both sunlight exposure and the presence of retinoic acid, June 2017 Newsletter, p. 10-15
  • FOXP3 as breakthrough in predicting survival and transformation, December 2009 Newsletter, p. 11-13, Article #5, p. 15-17

Fungal Infections, May 2009 Newsletter, p. 10-12, Article #3, p. 61-63

[ return to top ]

____________________________________________________________

G

GA-101

  • Tested in clinical trials as successor to rituximab, March 2012 Newsletter, p. 12-13
  • General information, Article #6, p. 29-30; August 2012 Newsletter, p. 13

Gazyva (Obinutuzumab, Gazyvaro)

  • “Latest Gazyva Obinutuzumab Data”, January 2017 Newsletter, p. 19-22
  • “Gazyva Obinutuzumab as a Replacement for Rituximab: What Can We Expect?”, May 2016 Newsletter, p. 3-14
  • “Improvements to Rituximab — No NOT GAZYVA Obinutuzumab”,  November 2016 Newsletter, p. 13-14
  • Side effects of Gazyva, May 2016 Newsletter, p. 6-8; 12-13
  • Gazyva follicular lymphoma clinical trial results alone and in combination with other drugs, May 2016 Newsletter, p. 3-14; March 2015 Newsletter, p. 12-15

GEM-P, Article #6, p.27

Gene Profiling and Diagnostic Testing

  • “Newly Diagnosed Follicular Lymphoma — To Treat or Not? New Genetic Test Provides Statistical Data to Help Guide the Decision”, September 2016 Newsletter, p. 17-19
  • Circulating tumor DNA (ctDNA) test, Article #2, p. 30; November 2016 Newsletter, p. 4-5
  • “Latest Genetic Data Predicts Follicular Lymphoma Transformation”,  September 2016 Newsletter, p. 20-22
  • Follicular lymphoma — testing for mutated genes with m7-FLIPI, September 2015 Newsletter, p. 4-16
  • New directions in genetic testing — implications for cancer patients, May 2015 Newsletter, p. 7-12
  • FoundationOne Heme (diagnostic genetic test for blood cancers), March 2015 Newsletter, p. 9-12
  • “Genetic Testing… Results Reinforce Importance of Lifestyle Choices”, April 2015 Newsletter, p. 9-11

Genetic Research 

  • Leading researchers find under and over-expressed “out of balance” genes in the epigenome are a “pivotal hallmark” of follicular lymphoma, January 2016 Newsletter, p. 17-20
  • Mutations,translocations and the role of the epigenome — we are moving toward a more sophisticated understanding of how follicular lymphoma develops and how natural regression can occur, November 2015 Newsletter, p. 5-7
  • “Repairing Mutations? Inheritance? New Grading System?”, June 2015 Newsletter, p. 8-11
  • Diagram depicting role of lifestyle, the epigenome and the genome as interrelated factors in cancer progression and regression, August 2015 Newsletter, p. 14-15
  • Gene MMP-9 , stress, and follicular lymphoma, December 2014 Newsletter, p. 17-23
  • Gene CDKN2A status predicts overall survival time for patients treated with rituximab, April 2015 Newsletter, p. 5-7
  • Gene MLH1 status can block response to CHOP, April 2015 Newsletter, p. 7-9
  • Genetic profiles as prognostic indicators for long-term survival, January 2015 Newsletter, p. 5-7; January 2014 Newsletter, p. 8-9: October 2013 Newsletter, p. 2-6; March 2006 Newsletter, p. 3-6
  • “New Developments in Diagnosing Follicular Lymphoma” , December 2014 Newsletter, p. 12-15
  • “The Genes Driving Follicular Lymphoma and Those that Can Reverse It”, January 2014 Newsletter, p. 3-9
  • Genetic research and new research findings re transformation, Article #4, p. 15-23
  • Genes associated with follicular lymphoma transformation, Article #4, p. 15-23; June 2014 Newsletter, p. 4-8
  • Review of genetic testing issues and new drug development, Article #5, p. 33-35
  • DNA repair genes and their role in managing follicular lymphoma, January 2014 Newsletter, p. 7-8
  • A third cancer management paradigm is emerging which is beginning to match lifestyle strategies with the epigenetic remediation of key ringleader genes driving cancer, Article #11, p. 1-24; Article #2, p. 4-6; November 2013 Newsletter, p. 3-6
  • Epigenetic anticancer effects of the 4P-GRS program: Article #3: Article #10; Article #11
  • Ringleader genes in fNHL and their effect on epigenetic expression, October 2013 Newsletter, p. 3-6: Article #11, p. 1-24; February 2013 Newsletter, p. 2-15
  • Epigenetics and natural regression of follicular lymphoma, Article #11, p. 20-23
  • Myc gene, a suspected ringleader gene driving fNHL, linked to glutamine, February 2013 Newsletter, p. 8-9; December 2012 Newsletter, p. 10-13
  • Lymphoma genetic profile completed, September 2012 Newsletter, p. 8-10
  • Gene EPHA7 an important gene for fNHL, October 2013 Newsletter, p. 3-6; December 2011 Newsletter, p. 8-9
  • “Will Genetic Profiling Influence the Management of Follicular Lymphoma?”, May 2013 Newsletter, p. 5-9
  • Combined gene and immunotherapy research experimental research results with leukemia patients, April 2013 Newsletter, p. 20-21
  • Gene MLL2 (KMT2D), connected to histone action, is discovered to be mutated and rendered inactive in 89% of newly diagnosed fNHL patients, January 2014 Newsletter, p. 5-7; October 2013 Newsletter, p. 3-6; August 2011 Newsletter, p. 22-24
  • Gene P53 and selenium supplementation, Article #11, p. 14-15; Article #3, p. 50; November 2008 Newsletter, p.9

Gerson therapy, Article #7, p. 50-51; April 2008 Newsletter, p. 14

Ginger

  • Ginger drink, Article #3, p.47-48; December 2015 Newsletter, p. 8-9:June 2008 Newsletter, p. 7-9
  • Epigenetic anticancer effects of ginger, Article #11, p.8
  • Ginger’s role in bowel health,  October 2016 Newsletter, p. 6-7
  • Ginger and exosomes, June 2015 Newsletter, p. 20-21: September 2014 Newsletter, p. 13-14
  • Ginger used to combat nausea during chemotherapy, June 2015 Newsletter, p. 19-20; June 2009 Newsletter, p. 18

Glucose Deprivation

  • Surprisingly dissimilar results found for effects of carbohydrate-rich foods on individuals, January 2016 Newsletter, p. 11-16
  • Epigenetic anti-cancer effects of glucose deprivation, Article #10, p. 22-24; Article #11, p. 9
  • Supplements known to affect blood glucose levels, April 2013 Newsletter, p. 7-9; Article #3, p.53
  • Dietary challenges in reducing sugar in the diet, January 2013 Newsletter, p. 5-9
  • Cinnamon found to help with glycaemic control, February 2013 Newsletter, p. 17-18
  • “Cancer as a Metabolic Disease”, November 2012 Newsletter, p. 5-15
  • Practicing glucose deprivation as part of a daily TNS program, July 2013 Newsletter, p. 8-10; November 2012 Newsletter, p. 12-15

Glutamine

  • Potentially harmful epigenetic effects of glutamine supplements and glutamates, Article #10, p. 26-27; Article #11, p. 9-10; March 2014 Newsletter, p. 14-15
  • Research shows glutamine promotes tumor growth in hypoxic conditions, March 2014 Newsletter, p. 14-15
  • Glutamine supplementation (including protein powders) as a possible trigger of transformation, Article #4, p. 14; November 2012 Newsletter, p. 9-10
  • “Sugar, Glutamine, and Cancer Genes”, April 2013 Newsletter, p. 3-7
  • February 2012 Newsletter, p. 3-8; September 2009 Newsletter, p. 10-11
  • Glutamine supplementation to be avoided as it is a key source of fuel for cancer cells, Article #3, p. 55; Article #10, p. 26-27; Article #11, p. 9-10; Article #7, p.43-44; December 2012 Newsletter, p. 10-13; November 2012 Newsletter, p. 9-10

Glycation

  • AGEs (advanced glycated end products), elevated blood sugar levels, and genetic damage, November 2012 Newsletter, p. 11-12

Glycolysis, June 2010 Newsletter, p. 3-6, July 2010 Newsletter, p. 13

Glyphosate (Roundup)

  • Glyphosate and toxic exposure risks, May 2017 Newsletter, p. 5-7
  • Roundup weedkiller (glyphosate) classified by the World Health Organization as a “probable carcinogen” linked to an increased risk of non-Hodgkin lymphoma, May 2015 Newsletter, p. 16-19

GMO (Genetically Modified) Foods

  • GMO foods and risk factors for cancer patients, August 2014 Newsletter, p. 24-25; May 2014 Newsletter, p. 8-10

Grades of Follicular Lymphoma, Article #2, p. 14-15

Grade 3 fNHL

  • “Grades 3A and 3B: Latest Essential Information”, December 2010 Newsletter, p. 13-15
  • General information: Article #2, p. 11-13; August 2008 Newsletter, p. 8-11; June 2008 Newsletter, p. 10-11; November 2007 Newsletter, p. 18-19; August 2007 Newsletter, p. 8-9; October 2005 Newsletter, p. 5-6

Grass Fed Beef, Bison and Lamb, Article #3, p. 54

Green Tea

  • Precaution against green tea extract use during chemotherapy, February 2009 Newsletter, p. 12-13
  • Green tea extract effectiveness and curcumin, November 2007 Newsletter, p. 7-8; July 2007 Newsletter, p. 5
  • Green tea extract and B-cell malignancies, January 2006 Newsletter, p. 3-5

GS-1101 (CAL-101)

  • Article #6, p. 30: August 2012 Newsletter, p. 8; August 2011 Newsletter, p. 17-19

[ return to top ]

_____________________________________________________

H

H Pylori bacteria, February 2007 Newsletter, p. 7; January 2007 Newsletter, p. 8-10; October 2005 Newsletter, p. 6-8

Hemoglobin

  • As a major indication of transformation, August 2008 Newsletter, p. 7-8; Article #2, p.34
  • Interpreting hemoglobin levels in blood tests, October 2014 Newsletter, p. 5-12; Article #5, p. 22-23; February 2010 Newsletter, p. 8-9

Hemolysis

  • How hemolysis can distort blood test results, October 2012 Newsletter, p. 18-19

Herbicides and Pesticides

  • As a risk factor for lymphoma, May 2017 Newsletter, p. 5-9: Article #11, p.6-7; Article #3, p. 63; March 2010 Newsletter, p. 7-9
  • Studies linking pesticide exposure with lymphoma, May 2017 Newsletter 5-9; July 2009 Newsletter, p. 10-11; March 2005 Newsletter, p. 4-6
  • Roundup weedkiller (glyphosate) classified by the World Health Organization as a “probable carcinogen” linked to an increased risk of non-Hodgkin lymphoma, May 2015 Newsletter, p. 16-19
  • Use of glyphosate, 2,4-D, Atrazine, and Dicamba, all associated with fNHL, is increasing, May 2017 Newsletter, p. 5-9
  • Pesticide residues in fruits and vegetables, October 2013 Newsletter, p. 9-13
  • Links to lists of fruits and vegetables with lowest and highest amounts of pesticides, June 2016 Newsletter, p. 16-17
  • Natural weed killer formula, April 2007 Newsletter, p. 8-9

Histology (see Diagnosis)

Histone Deacetylase (HDAC) Inhibitors

  • Broccoli and Brussels sprouts are natural HDAC inhibitors, Article #10, p. 24-25; Article #11, p. 16; April 2012 Newsletter, p. 11-14; May 2011 Newsletter, p. 11-13, Article #3, p. 40; December 2010 Newsletter, p.5-6, November 2010 Newsletter, p. 8-9
  • Potential of HDAC inhibitors in helping to manage fNHL, Article #10, p. 24-25; Article #11, p. 16; July 2011 Newsletter, p. 6-10, October 2010 Newsletter, p. 6-7, August 2010 Newsletter, p. 6-9, June 2010 Newsletter, p. 15-17, August 2006 Newsletter, p. 7-9
  • Sulforaphane as a natural HDAC inhibitor in foods, Article #10, p. 24-25; Article #11, p. 16; Article #3, p.40; May 2011 Newsletter, p. 10-13, February 2011 Newsletter, p. 4-5

Hyperthermia/Heat Therapy/Hot Baths

  • Boosting chemo effectiveness with intraperitoneal hyperthermic chemotherapy, October 2013 Newsletter, p. 14-15
  • Hyperthermia during chemotherapy, Article #8, 3-8; Article #7, p. 25-26
  • Hyperthermia clinical trial results, Article #8, p. 3-8; October 2009 Newsletter, p. 9-11

[ return to top ]

________________________________________________________

I

Ibrutinib (Imbruvica)

  • Careful assessment of ibrutinib (imbruvica) recommended for those considering it as a treatment for follicular lymphoma, January 2016 Newsletter, p. 9-10
  • “Ibrutinib IMBRUVICA Side-Effects (Unbiased Verified Information)”, April 2014 Newsletter, p. 3-8; 11-13
  • Results from a Phase 1 trial using Imbruvica with relapsed follicular lymphoma patients, January 2014 Newsletter, p. 13-16
  • Ibrutinib and the BTK gene — off-target reactivity, December 2013 Newsletter, p. 15-18
  • Ibrutinib … a Concern ; Immunity, side effects, clinical trials for follicular lymphoma, BTK gene; September 2013 Newsletter, p. 3-13
  • Ibrutinib’s side effects when used as a genetically-based therapy for treating follicular lymphoma, Article #7, p. 47-50; October 2013 Newsletter, p. 5

Idelalisib (Zydelig)

  • “Zydelig — Idelalisib — Caution (new concerns published re clinical trials including FDA Alert)”, June 2016 Newsletter, p. 4-6; April 2016 Newsletter, p. 10-12
  • Careful assessment of idelalisib (zydelig) recommended for those considering it as a treatment for follicular lymphoma, January 2016 Newsletter, p. 9-10
  • “Idelalisib (Zydelig) Approved for Relapsed Follicular Lymphoma…BUT”, August 2014 Newsletter, p. 7-9
  • “Idelalisib (Zydelig)… Side-Effects, Effectiveness (New England Journal of Medicine, March 2014)”, April 2014 Newsletter, p. 3-4; 8-13
  • Concerns with Idelalisib (Zydelig) and serious side effects, June 2016 Newsletter, p.4-6; April 2016 Newsletter, p. 10-12, January 2016 Newsletter, p. 9-10; August 2014 Newsletter, p. 7-9; April 2014 Newsletter, p. 3-4 and 8-13; December 2013 Newsletter, p. 15-18; Article #7, p. 47-50
  • Results from a Phase 2 trial using Idelalisib with relapsed indolent lymphoma patients, January 2014 Newsletter, p. 15-16

Immunity

  • “Seven Surprising Perspectives about the Immune System and fNHL”, June 2013 Newsletter, p. 3-12
  • “Optimizing Immunity for the Winter Season”, January 2013 Newsletter, p. 11-14
  • Fallacy of the “boosting the immune system” concept, November 2007 Newsletter, p.12-13
  • Immunity, cancer and inflammation, January 2009 Newsletter, p. 5-7

Immunoglobulins

  • Immunoglobulin test results and what they mean, February 2015 Newsletter, p. 18-19
  • Recommendation to get Ig levels (IgA, IgG, IgM) tested on a regular basis, January 2012 Newsletter, p. 15-17
  • Why WBC blood tests (lymphocytes & neutrophils) need to be supplemented with immunoglobulin tests, May 2013 Newsletter, p. 11-13
  • Immunoglobulins and maintenance rituximab, Article #7, p. 26-29; September 2012 Newsletter, p. 3-8; November 2011 Newsletter, p. 2-5
  • Immunoglobulins in blood tests, normal range, Article #5, p. 26-27; Article #3, p. 62-63
  • Immunoglobulins and colostrum, Article #3, p.63; December 2010 Newsletter, p. 18
  • February 2010 Newsletter, p. 6-8
  • Risks associated with below normal Immunoglobulins, Article #7, p. 28-29; April 2010 Newsletter, p. 3-6
  • Details related to sub-normal vs. optimal levels of Immunoglobulins, May 2010 Newsletter, p. 15-16

Immunotherapy, October 2016 Newsletter, p. 15

Inflammation and cancer

  • FOXP3+ Tregs, a potent prognostic indicator of long-term survival with fNHL, is a master regulator of inflammation, June 2017 Newsletter, p. 10-15
  • General information: March 2017 Newsletter, p. 9-10; July 2016 Newsletter, p. 15-19; January 2008 Newsletter, p. 14-16; October 2007 Newsletter, p. 3-6; February 2007 Newsletter, p. 4-6; May 2016 Newsletter, p. 15-20

Insulin levels and cancer, October 2014 Newsletter, p. 13-15; Article #10, p. 22-24; November 2012 Newsletter, p. 10-11; February 2011 Newsletter, p. 17; February 2010 Newsletter, p. 12-14

Integrative Medicine

  • Integrative medicine as distinct from “alternative medicine”, May 2009 Newsletter, p. 4-5
  • “The Winning Battle Plan: Risks with an Alternative Approach”, October 2013 Newsletter, p. 7-9
  • “Integrative Medicine … Content, Context and Psychology”, August 2010 Newsletter, p. 10-12

Iodine, April 2013 Newsletter, p. 24-25; Article #3, p. 58

Iron

  • Need for fNHL patients to avoid iron supplements, April 2017 Newsletter, p. 17-18; January 2015 Newsletter, p. 15; May 2013 Newsletter, p. 16-18; Article #7, p. 14
  • Iron supplements as a possible trigger for transformation, Article #4, p. 14; Article #7, p.14

 

[ return to top ]

_________________________________________

J

[ return to top ]

_________________________________________________

K

[ return to top ]

Kelp Extract, Article #3, p. 58

Ki-67, Article #5, p. 17; Article #2, p. 31, May 2013 Newsletter, p. 18-19

Kirschbaum, Dr. Mark

  • New drug development based on epigenetic processes, July 2011 Newsletter, p.1-4, June 2011 Newsletter, p. 11, May 2011 Newsletter, p. 21-23

________________________________________________

L

LDH

  • LDH test, Article #5, p. 23
  • LDH and tomato juice, March 2017 Newsletter, p. 15-16
  • Exercise can affect LDH test results, July 2013 Newsletter, p. 23-24
  • Elevated LDH and transformation, Article #4, p.5-6; Article #5, p.23; Article #2. p.34

Leonard, Dr. John

  • Expert commentary on 2016 clinical trial results comparing Rituxan and Gazyva, January 2017 Newsletter, p. 20

Lifestyle Strategies (see also Targeted Natural Strategies)

  • “Epigenetic Regulators of Follicular Lymphoma: A Reference Guide”, Article #11
  • “Getting Follicular Lymphoma Cells to Die on Their Own”, Article #10
  • “Follicular Lymphoma: Natural Strategies for Long-Term Survival: A Four Pillar Approach”, Article #3
  • Ringleader fNHL genes and enzymes and lifestyle strategies affecting their epigenetic expression, February 2013 Newsletter, p. 2-15
  • High tumor microenvironment expression of CD7 and dietary lifestyle factors in fNHL patients linked to increased survival time, December 2012 Newsletter, p. 8-10
  • Updated dietary strategies, Article #3, p. 42-60
  • Research studies demonstrate dramatically reduced risk of breast cancer in women practicing healthy diet and lifestyle strategies, Article #10, p.15; January 2012 Newsletter, p. 21-23; April 2011 Newsletter, p. 11-12
  • “Making Changes in Life Following Diagnosis”, May 2013 Newsletter, p. 3-5
  • Epigenetics and lifestyle strategies, Article #3, p. 7-14; Article #11, p. 1-25; Article #10, p. 13-33; Article #2, p. 4-9; May 2011 Newsletter, p. 2-24, October 2008 Newsletter, p. 9-10; July 2008 Newsletter, p. 3-6; Article #2, p. 4-6
  • Using lifestyle strategies during periods of dynamic observation, July 2008 Newsletter, p. 3-6.
  • “The New Direction in Cancer Research … We’re Already on the Way”, August 2010 Newsletter, p. 3-10

Long-Term Survival (also see Planning Horizon)

  • Overall Survival Statistics, Article #2, p. 25-29
  • Prognostic Indicators for overall survival, Article #2, p. 29-32
  • No overall survival advantage found between watchful waiting, chemoimmunotherapy, and initial treatment with rituximab monotherapy,  February 2016 Newsletter, p. 4-6
  • Event-Free Survival (EFS) as a prognostic indicator, January 2015 Newsletter, p. 11-14
  • “Our Four Groups of Members: Who They Are and What They Need”, September 2011 Newsletter, p. 3-17
  • “Grateful for 25 Years Since Diagnosis: The Key Strategic Factors”, July 2013 Newsletter, p. 2-7
  • “The “How to” Details for Lengthening Your Life — Getting into the Thrive Zone with Epigenetics”, May 2011 Newsletter, p. 2-24
  • “From Knowledge to Success… 9 Essential Steps in Managing fNHL”, March 2011 Newsletter, p. 3-9
  • “The Five Key Things That Got Me This Far”, January 2011 Newsletter, p. 3-9
  • “Cracking the Code for Entering the Thrive Zone”, December 2010 Newsletter, p. 4-6
  • “Strategic Requirements for the Thrive Zone”, December 2010 Newsletter, p. 6-8
  • “The Seven Premises in Understanding and Managing fNHL”, November 2010 Newsletter, p. 3-12
  • Key factors influencing long-term survival, August 2009 Newsletter, p. 3-9
  • An overall strategy for managing fNHL for long-term success, February 2009 Newsletter, p. 2-6
  • Planning for transformation: Most important considerations, Article #6, p.16; January 2009 Newsletter, p. 3-4
  • ” 40 Must Know Things Learned After 22 Years — Especially Important for the Newly Diagnosed”, July 2010 Newsletter, p. 4-10
  • ” Maintaining a Clinical Remission”, September 2010 Newsletter, p. 6-9
  • Depression and long-term survival, July 2008 Newsletter, p. 11-12
  • New data on overall survival for fNHL patients diagnosed before the age of 40, November 2015 Newsletter, p. 15-17
  • “New Research in Forecasting Survival Time”, March 2011 Newsletter, p. 10-12
  • Personal characteristics of long-term survivors, February 2010 Newsletter, p. 11-12
  • Stanford research on overall survival (OS), Article #2, p. 26-29; December 2007 Newsletter, p. 5-7; May 2005 Newsletter, p. 7-10
  • Three phases in the long-term management of follicular lymphoma, November 2007 Newsletter, p. 3-6
  • Significance of relapse in long-term management and survival, September 2007 Newsletter, p. 4-5
  • Genetic profiling as a prognostic indicator for long-term survival, March 2006 Newsletter, p. 3-6

Lymph Fluid

  • How to purify the lymph fluid, Article #7, p. 37-38; December 2015 Newsletter, p.24-25; May 2016 Newsletter, p. 15-20; Article #3, p.31
  • The fascinating lymphatic system, Article #2, p. 10-12

Lymphocytes

  • Low lymphocyte counts in blood tests, October 2014 Newsletter, p. 5-12

Lymphoma Map for USA (all Non-Hodgkin’s lymphomas), February 2012 Newsletter, p. 18-21; July 2009 Newsletter, p. 10

Lymphoma Specialists

  • Guidelines for establishing patient-specialist relationship, Article #3, p. 69-70; January 2006 Newsletter, p. 8-9
  • Web link to North America’s top lymphoma specialists, Article #3, p. 69

[ return to top ]

________________________________________________

M

m7- FLIPI

  • m7-FLIPI as a potentially new and better forecasting tool, September 2015 Newsletter, p. 4-6; 10-14: Article #2, p.33

Macrophages, January 2006 Newsletter, p. 7-8

Magnesium, Article #3, p. 57, December 2016 Newsletter, p. 19-20

Maintenance Rituximab

  • “Maintenance Rituximab — for How Much Longer?” (Update to March 2016), March 2016 Newsletter, p. 4-16
  • Member feedback re pros and cons of Maintenance Rituximab, May 2017 Newsletter, p. 16-17
  • “Maintenance Rituximab Now Considered Optional by Experts”, September 2016 Newsletter, p. 12-15
  • “The Impact of Rituximab on Long-Term Immunity”, September 2016 Newsletter, p. 15-17
  • “End of Rituximab Maintenance for Low-Tumor Burden Follicular Lymphoma”, November 2014 Newsletter, p. 5-6
  • “Strategies to Stay Healthy While on Maintenance Rituximab”, March 2015 Newsletter, p. 16
  • Study published in October 2014 shows failure of Maintenance Rituximab (MR) to produce significantly beneficial outcomes in patients receiving MR as compared to those patients receiving rituximab only in the event of relapse, October 2014 Newsletter, p. 15-17
  • “Maintenance Rituximab Update, Pros, Cons, Strategies”, January 2014 Newsletter, p. 17-18
  • “More Cautions re Maintenance Rituximab”, June 2014 Newsletter, p. 15-17
  • “Update to September 2012”, September 2012 Newsletter, p. 3-8
  • Testing immunoglobulin (Ig) levels advised before and after treatment with maintenance rituximab, December 2014 Newsletter, p. 9-11
  • General information, Article #7, p. 26-29
  • Compromised immunity and maintenance rituximab, Article #7, p. 28-29
  • Study shows low tumor burden fNHL patients on watch and wait do just as well in first four years as low tumor burden patients treated with MR, October 2012 Newsletter, p. 11
  • Video link to explanation given by Dr. Brad Kahl discussing results of 2011 RESORT study showing MR has no long term survival advantage for patients as compared with rituximab treatment as needed, October 2012 Newsletter, p. 11

Manuka honey, March 2009 Newsletter, p. 12-14

Master Strategy

  • The master strategy for follicular lymphoma regression, December 2015 Newsletter, p. 28-29 (also see our video under “Videos” tab) 

Meditation, June 2010 Newsletter, p. 13-15

Melatonin

  • Generating natural melatonin with sunlight, Article #3, p. 36; March 2014 Newsletter, p. 20
  • Melatonin and circadian rhythm, p. 35

Metabolic Disease

  • “Cancer as a Metabolic Disease”, November 2012 Newsletter, p. 5-15
  • The “Warburg Effect” — Why it is important for spontaneous regression of follicular lymphoma, Article #10, p. 6-7; 22-24

Metformin, July 2016 Newsletter, p. 19-20

Methylation

  • DNA Methylation and natural regression of follicular lymphoma, August 2015 Newsletter, p. 2-15
  • May 2014 Newsletter, p. 8-10; April 2012 Newsletter, p. 12-13; December 2010 Newsletter, p. 6-7, November 2010 Newsletter, p. 8, October 2010 Newsletter, p. 6-7

Mercury Dental Fillings, October 2012 Newsletter, p. 19-20; September 2007 Newsletter, p. 13-14

Microbiome , June 2017 Newsletter, p. 12-15, October 2016 Newsletter, p. 4-15; April 2017 Newsletter, p. 7-12; January 2017 Newsletter, p. 15-16; January 2016 Newsletter, p. 11-16; June 2014 Newsletter, p. 17-20; November 2013 Newsletter, p. 6-9, Article #3, p. 44

Microenvironment

  • High tumor microenvironment expression of CD7 and dietary lifestyle factors in fNHL patients linked to increased survival time, December 2012 Newsletter, p. 8-10
  • Immune nodal microenvironment and long-term survival, January 2015 Newsletter, p. 5-10; Article #11, p. 20-25; Article #10, p. 7; Article #2, p. 36-37;  December 2014 Newsletter, p. 16-17; January 2010 Newsletter, p. 12-14; April 2008 Newsletter, p. 2-5
  • Original, symbolic portrayal of “corralling” lymphoma in nodal microenvironment, December 2009 Newsletter, p. 3-11
  • Epigenetics and nodal microenvironment, Article #10, p. 7; December 2011 Newsletter, p.7-8; March 2009 Newsletter, p. 2-4
  • CD4 and CD6 biomarkers and nodal microenvironment, February 2010, p. 3-6

Milk Thistle

  • Epigenetic anti-cancer effects of milk thistle (silibinin), Article #11, p.11
  • Article #3, p. 58
  • Bowel inflammation and milk thistle, October 2016 Newsletter, p. 11-12

MIME, Article #6, p.27

Mitochondria

  • Warburg effect (cancer as a metabolic disorder), Article #10, p. 6-7; Article #3, p. 28, November 2010 Newsletter, p. 10, June 2010 Newsletter, p.3-6; May 2016 Newsletter, p. 15-20
  • Resveratrol and mitochondria, Article #10, p.24; Article #3, p. 58; December 2010 Newsletter, p. 7-8, July 2010 Newsletter, p. 13-15
  • Exercise and mitochondrial stimulation, July 2013 Newsletter, p. 10-11

Monoclonal Antibodies, January 2006 Newsletter, p. 5-6

MRI

  • Using MRI scans for fNHL, Article #5, p. 31-32; September 2013 Newsletter, p. 18-21

MRSA, June 2012 Newsletter, p. 22-23; February 2011 Newsletter, p. 11-12; May 2010 Newsletter, p. 14-15; Article #3, p. 61

mTOR

  • The mTOR gene, alcohol, and lymphoma, November 2013 Newsletter, p. 9-11
  • Quercetin and the mTOR gene, November 2013 Newsletter, p. 13-15

Myc Gene

  • Connection found between epigenetic changes in cancer cells and the Myc gene, Article #10, p. 26-27; Article #11, p. 10-11; 17; 20-25; December 2012 Newsletter, p. 10-13
  • Testing for Myc gene expression, Article #4, p.22
  • Vitamin D found to inhibit production and function of protein cMyc, Article #10, p.13-16; February 2013 Newsletter, p. 6-8

Music, January 2010 Newsletter, p. 22; July 2006 Newsletter, p. 8-9

[ return to top ]

N

Nanotechnology

  • 2013 research using nanotechnology to knock out aggressive breast cancer tumors, November 2013 Newsletter, p. 17
  • Research on the use of nanotechnology for gene remediation in brain cancer, November 2013 Newsletter, p. 17
  • Used in early detection of cancer, October 2009 Newsletter, p. 17

Neurotoxins, Article #3, p. 64

NF-Kappa B pathway

  • Berries down-regulate NF Kappa B, October 2009 Newsletter, p. 16-17
  • Experimental drugs targeting NF Kappa B pathway, October 2009 Newsletter, p. 17-18
  • NF-Kappa B pathway, high sugar intake, and inflammation, February 2008 Newsletter, p. 7
  • NF-Kappa B pathway and tocotrienols, January 2008 Newsletter, p. 17-18

Night Sweats, November 2010 Newsletter, p. 14-15

Nutrition

  • “Applying Nutrition Properly: The Two Population Fact”, April 2016 Newsletter, p. 4-8

[ return to top ]

________________________________________________________

O

Omega 6:3 ratio, Article #11, p. 11

Oncogenes, August 2015 Newsletter, p. 8-11

Oranges, Article #3, p. 52

Organic Foods, August 2014 Newsletter, p. 21-23

Organochlorines

  • As a risk factor for lymphoma, Article #11, p.6-7; Article #3, p. 63; October 2007 Newsletter, p. 8-9
  • Risk factors associated with chlorinated water, May 2017 Newsletter, p. 10-12; April 2012 Newsletter, p. 16-17; April 2009 Newsletter, p. 8-9
  • Troclosan in soaps interacting with chlorinated water, June 2005 Newsletter, p. 11-13

Ornish, Dr. Dean

  • “With Thanks, Respect and Hope”, April 2011 Newsletter, p. 7
  • Breakthrough research on epigenetics and prostate cancer, Article #10, p. 4-6; June 2008 Newsletter, p. 3-6
  • Need for fNHL research on lifestyle changes and epigenetics patterned on Ornish’s prostate cancer research, February 2013 Newsletter, p. 17-20; March 2011 Newsletter, p. 18-20; September 2010 Newsletter, p. 11-13

Oxygenation, July 2013 Newsletter, p. 11-13

[ return to top ]

__________________________________________________________

P

PACE, Article #6, p.27

Paradigm Shift (in understanding and treating fNHL), August 2015 Newsletter (entire); October 2014 Newsletter, p. 4-5; Article #10, p. 3-4; Article #2, p. 4-6; March 2014 Newsletter, p. 10-11; April 2006 Newsletter, p. 5-9; December 2005 Newsletter, p. 5-7

Paraneoplastic Syndrome, Article #3, p.66; November 2010 Newsletter, p. 15-16

PCR (R-PCR), January 2009 Newsletter, p. 4-5.

PEP-C  April 2008 Newsletter, p. 9-10

Pesticides (see Herbicides and Pesticides)

PET scans

  • Research on high frequency of false positive PET scans in regard to diagnosis of relapsed lymphoma, Article #5, p. 30-31; June 2011 Newsletter, p. 18-20
  • Risks of over-exposure to radiation, Article #5, p. 28-31; Article #10, p. 23; May 2015 Newsletter, p. 12-16; January 2010, p. 14-17
  • Limitations of PET scans, Article #5, p. 30-31; September 2007 Newsletter, p. 5-7; May 2005 Newsletter, p. 10

Pidilizumab (CT-011)

  • Pidilizumab (CT-011) Looks Very Promising (Better then Ibrutinib?)”, April 2014 Newsletter, p. 13-15

PI3K/Akt Signaling Pathway

  • PI3K (delta) and Idelalisib, December 2013 Newsletter, p. 15-18
  • Quercetin as a dual-specific activator of mTOR and the PI3K/Akt signaling pathway, November 2013 Newsletter, p. 13-15
  • PI3K as a target for new drugs to treat follicular lymphoma, November 2013 Newsletter, p. 15

Planning Horizon (also see Long-Term Survival)

  • “Our Four Groups of Members: Who They Are and What They Need”, September 2011 Newsletter, p. 3-17
  • “Grateful for 25 Years Since Diagnosis: The Key Strategic Factors”, July 2013 Newsletter, p.2-7
  • “From Knowledge to Success … 9 Essential Steps in Managing fNHL”, March 2011 Newsletter, p. 3-9
  • “The Five Key Things That Got Me This Far”, January 2011 Newsletter, p. 3-9
  • “Cracking the Code for Entering the Thrive Zone”, December 2010 Newsletter, p. 4-6
  • “Strategic Requirements for the Thrive Zone”, December 2010 Newsletter, p. 6-8
  • Factors to consider in planning for 20 ++ years of survival, February 2010 Newsletter, p. 2-6; November 2009 Newsletter, p. 3-5; November 2006 Newsletter, p. 5-9
  • Planning for transformation: Most important considerations, Article #6, p.16; January 2009 Newsletter, p. 3-4
  • An overall strategy for managing fNHL for long-term success, February 2009 Newsletter, p. 2-6
  • “40 Must Know Things Learned After 22 Years — Especially Important for the Newly Diagnosed”, July 2010 Newsletter, p. 4-10
  • ” Maintaining a Clinical Remission”, September 2010 Newsletter, p. 6-9
  • Three phases in the long-term management of follicular lymphoma, November 2007 Newsletter, p. 3-6
  • Significance of relapse in long-term management and survival, September 2007 Newsletter, p. 4-5

Plastics, May 2017 Newsletter, p. 12-14; February 2010 Newsletter, p. 10-11; February 2008 Newsletter, p. 10-11

Phytochemicals

  • Suppression of cell-signalling pathways, October 2006 Newsletter, p. 8-9; December 2004 Newsletter, p. 9-10

Pomegranate Juice, Article #3, p. 56; July 2006 Newsletter, p. 5

Prebiotics, March 2017 Newsletter, p. 11-13

Prednisone, March 2010 Newsletter, p. 17-18

Prevention

  • Lifestyle strategies and cancer prevention, Article #2, p. 4-6; November 2016 Newsletter, p. 6-10;  February 2014 Newsletter, p. 11-13

Probiotics, October 2016 Newsletter, p. 9Article #11, p. 12

Problematic Nodes, Article #6, p. 8-9

Progression-Free Survival,  May 2016 Newsletter, p. 9-12; April 2009 Newsletter, p. 7-8

Protein Powder Supplements

  • Protein powder supplements are foods to avoid for cancer patients, Article #10, p. 26-27; Article #11, p. 9-10; Article #7, p. 43-44; December 2012 Newsletter, p. 12-13; Article #3, p. 55
  • Protein powders, glutamine, and transformation, Article #4, p.14
  • Avoidance advised concerning whey protein, Article #10, p. 26-27; Article #3, p. 55; June 2012 Newsletter, p. 17-19

PubMed, May 2010 Newsletter, p. 18

Pumpkin Seeds, Article #3, p. 48

Psychological Factors and treatment options, Article #1; Article #6; October 2008 Newsletter, p. 7-8

[ return to top ]

________________________________________________________

Q

Quercetin

  • Epigenetic anti-cancer effects of quercetin, Article #11, p. 13; November 2013 Newsletter, p. 13-15
  • Quercetin in apples “natural mimic” of many enzyme-based cancer therapies now under development, October 2012 Newsletter, p. 21-22; Article #3, p.52; November 2013 Newsletter, p. 13-15

[ return to top ]

_____________________________________________________________

R

R-Bendamustine (see Bendamustine)

R-CHOP

  • Importance of reserving use of R-CHOP for transformation, Article #4, p. 8-9; Article #6, p. 5-8
  • Comparison of R-CHOP and R-Bendamustine when used as an initial treatment, Article #7, p. 24-25; August 2011 Newsletter, p. 11-14
  • Gene MLH1 status can block response to CHOP, April 2015 Newsletter, p. 7-9
  • General information, Article #4, p. 1-9; Article #6, p. 19-20; August 2012 Newsletter, p. 9-10; Article #7, p.11-12
  • Critical information on possible shortages of chemotherapy drugs used to treat transformation, December 2010 Newsletter, p. 15-16
  • As treatment for transformation, Article #4, p. 8-9
  • CHOP and the heart, July 2016 Newsletter, p. 19-20;  April 2010 Newsletter, p. 21-23
  • Beet root juice and metformin during R-CHOP treatment, July 2016 Newsletter, p. 19-20
  • R-CHOP as a choice for initial therapy, Article #7, p. 19-20; Article #6, p.19-20.
  • Comparative data for R-CHOP and Bendamustine as choice for initial therapy, February 2011 Newsletter, p. 14-17
  • Dose-dense R-CHOP, March 2005 Newsletter, p. 6-8
  • Using Co-Enzyme Q-10 when receiving CHOP, October 2010 Newsletter, p.21, Article #8, p.9; March 2009 Newsletter, p. 10
  • R-CVP vs. R-CHOP with managerial implications, April 2009 Newsletter, p. 2-5
  • Doxorubicin caution, January 2008 Newsletter, p. 18-19
  • ECG suggested before treatment with R-CHOP, February 2011 Newsletter, p. 19-20
  • Increased potential of R-CHOP to markedly increase survival rates when reserved for probable event of transformation, August 2008 Newsletter, p. 7-8
  • Valsartan to prevent chronic doxorubicin-induced toxicity, April 2007 Newsletter, p. 8-9

R-CP, Article #6, p.27

R-CVP

  • General information, Article #6, p.17-18, August 2012 Newsletter, p. 10-11
  • As choice for initial therapy, Article #6, p.17-18.
  • R-CVP vs. R-CHOP with managerial implications, April 2009 Newsletter, p. 2-5

R-CyP, February 2008 Newsletter, p. 2-5; August 2007 Newsletter, p. 7-8

R-DHAOx, January 2010 Newsletter, p. 17-19

R-ESHAP, Article #6, p. 26

R-FC, Article #6, p. 16; July 2007 Newsletter, p. 10-11

R-FND, Article #6, p. 16;

R-GDP

  • Article #6, p. 26, Article #4, p.9-10; August 2012 Newsletter, p. 14
  • “The Merits of R-GDP (New Research plus Personal Experience)”, November 2014 Newsletter, p. 21-22

R-GCVP, Article #4, p. 10-11; March 2014 Newsletter, p. 8-9

R-ICE, Article #6, p. 26

R-PCR (PCR), Article #6, p.27; January 2009 Newsletter, p. 4-5.

Radiation

  • “Low Dose Radiation Update with a Detailed Personal Account”, December 2013 Newsletter, p. 5-7
  • General discussion of research pertaining to the use of low dose field radiation therapy (LDIFRT) in treating fNHL, Article #6, p. 20-21; August 2012 Newsletter, p. 14; October 2011 Newsletter, p. 12-13; January 2011 Newsletter, p. 12-14
  • Lymphoma in the eye region and radiation treatments, September 2014 Newsletter, p. 11-12
  • “Caution re Eight or More CT Scans Plus PET”, May 2015 Newsletter, p. 12-16
  • Tocotrienols and their potential for mediating radiation damage, July 2013 Newsletter, p. 19-22.
  • Effectiveness of radiation in treating fNHL, September 2010 Newsletter, p. 5-6
  • Dried plums can provide protection from radiation damage, July 2016 Newsletter, p. 20
  • Radiation for treatment of nodes of cosmetic concern, Article #7, p. 35-36
  • Radiation and early stage lymphoma, June 2009 Newsletter, p. 14-15
  • Radiation treatment of “limited stage” fNHL patients associated with possible increase in risk for transformation, December 2012 Newsletter, p. 16-17
  • Overview of use in the treatment of fNHL, April 2009 Newsletter, p. 5-6
  • Intensity Modulated Radiation Therapy (IMRT), October 2011 Newsletter, p. 12-13; August 2007 Newsletter, p. 10

Rainbow Salad, Article #3, p.56

Raspberries, Article #3, p. 49

Red Palm Oil

  • Epigenetic anti-cancer effects of tocotrienols in red palm oil, Article #11, p. 17, February 2016 Newsletter, p. 21; July 2013 Newsletter, p. 19-22; February 2013 Newsletter, p. 9-10; Article #3, p.50-51; March 2011 Newsletter, p. 12-13; April 2009 Newsletter, p.12-14; June 2007 Newsletter, p.5; April 2007 Newsletter, p. 9-10
  • Red palm oil may help to counteract negative effects of radiation, May 2015 Newsletter, p. 14-16
  • Instructions for mixing and consuming red palm oil, June 2016 Newsletter, p. 17-18
  • Red palm oil and gene p53, June 2015 Newsletter, p. 21-22

Relapse

  • How to prevent or delay relapse after first treatment, October 2015 Newsletter, p. 19-23
  • “The Critical Window of Opportunity in Managing Follicular Lymphoma. Don’t Miss It”,  February 2017 Newsletter, p. 9-11
  • Treatment options in the event of relapse after treatment with R-Benda, October 2015 Newsletter, p. 13-19
  • Guidelines for when to treat relapse situations, Article #6, p. 10-11; August 2013 Newsletter, p. 19-21
  • September 2007 Newsletter, p. 4-5

Reno, Jamie, review of book, “Hope begins in the dark: Fifty lymphoma survivors tell their exclusive life stories”, February 2008 Newsletter, p. 15

Restless Leg Syndrome, November 2010 Newsletter, p. 15, November 2009 Newsletter, p. 18-19

Resveratrol

  • Epigenetic anti-cancer effects of resveratrol, Article #11, p. 13-14
  • New, reduced dosage suggested for daily supplementation with trans-resveratrol, May 2012 Newsletter, p. 15-16; Article #3, p.58
  • How to calculate the “trans” component in resveratrol supplements and caution re deceptive labeling of resveratrol supplements, November 2011 Newsletter, p. 16-17
  • Resveratrol is on the “A” Team, March 2010 Newsletter, p.16-17
  • Suggestions for ingesting resveratrol,  April 2011 Newsletter, p. 21-22, December 2010 Newsletter, p. 11
  • Research updates on resveratrol, February 2013 Newsletter, p. 12-13; December 2010 Newsletter, p. 10-12
  • Resveratrol bioavailability, July 2009 Newsletter, p. 14-15
  • Research on safe dosage, August 2010 Newsletter, p. 17
  • Effect on mitochondria, May 2011 Newsletter, p. 13-15, November 2010 Newsletter, p. 10, June 2010 Newsletter, p. 6-7, July 2010 Newsletter, p. 13-15, September 2010 Newsletter, p. 8; Article #3, p. 58
  • How to read supplement labels to determine the correct dosage for trans-resveratrol, July 2010 Newsletter, p. 14-15
  • Resveratrol ability to block cancer cell telomerase, March 2010 Newsletter, p. 6
  • Resveratrol, the bcl-6 pathway, and the announcement of a “new class” of lymphoma drugs in April 2010, June 2010 Newsletter, p. 6-7
  • Summary of research studies on anti-cancer effects of resveratrol, June 2009 Newsletter, p. 11-14
  • Research on resveratrol and transformed fNHL cells, Article #4, p. 24; June 2012 Newsletter, p. 14-16; June 2009 Newsletter, p. 11-12
  • Precautions on dosing with high-dosage trans-resveratrol, June 2009 Newsletter, p. 13-14

Retinoids

  • Retinoids crucial for the proliferation of FOXP3+ Treg cells which are crucial for long-term survival with fNHL, June 2017 Newsletter, p. 6-9, 12-15
  • Best food sources for vitamin A,  June 2017 Newsletter, p. 6-9: February 2016 Newsletter, p. 14-22
  • Epigenetic anticancer effects of retinoids; Article #11, p. 14
  • Cod liver oil as a daily supplement, Article #3, p. 58
  • Retinoids and bowel health, October 2016 Newsletter, p. 12
  • Assuring adequate amounts of retinoids in the diet is tricky, October 2016 Newsletter, p. 16-20

Revlimid (Lenalinomide)

  • General information, Article #6, p. 29; August 2012 Newsletter, p. 14-15; May 2008 Newsletter, p. 14

Rituximab (also see Maintenance Rituximab)

  • “Maintenance Rituximab — for How Much Longer?” (Update to March 2016), March 2016 Newsletter, p. 4-16
  • Member feedback re pros and cons of Maintenance Rituximab, May 2017 Newsletter, p. 16-17
  • “Maintenance Rituximab Now Considered Optional by Experts”, September 2016 Newsletter, p. 12-15
  • “The Impact of Rituximab on Long-Term Immunity”, September 2016 Newsletter, p. 15-17
  • “Improvements to Rituximab — No NOT GAZYVA Obinutuzumab”,  November 2016 Newsletter, p. 13-14
  • General information, Article #6, p. 13; August 2012 Newsletter, p. 15-17; “Rituximab … Expert Balanced Opinions .. a Must Read”, March 2011 Newsletter, p. 9-10; Article #6, p. 2-4
  • Important results from RESORT Trial, January 2012 Newsletter, p. 10-15; December 2011 Newsletter, p. 3-7
  • Maintenance rituximab (MR) , November 2014 Newsletter, p. 5-6; October 2014 Newsletter, p. 15-17; Article #6, p. 18-19; Article #7, p. 20-22; “More Cautions re Maintenance Rituximab”, June 2014 Newsletter, p. 15-17; “Update to September 2012”, September 2012 Newsletter, p. 3-8
  • “End of Rituximab Maintenance for Low-Tumor Burden Follicular Lymphoma”, November 2014 Newsletter, p. 5-6
  • No overall survival advantage found between watchful waiting, chemoimmunotherapy, and initial treatment with rituximab monotherapy,  February 2016 Newsletter, p. 4-6
  • Gene CDKN2A status predicts overall survival time for patients treated with rituximab, April 2015 Newsletter, p. 5-7
  • “Strategies to Stay Healthy While on Maintenance Rituximab”, March 2015 Newsletter, p. 16
  • Rituximab and beta glucans, Article #8, p. 8-9
  • Research study finds prolonged use of rituximab heightens risk of suppressed long-term immunity, October 2011 Newsletter, p. 9-12
  • Rituximab and exercise, July 2008 Newsletter, p. 11
  • Rituximab and colony growth stimulating factors, December 2004 Newsletter, p. 8-9
  • Rituximab and risk of progressive multifocal leukoencephalopathy (PML), July 2009 Newsletter, p. 4-8
  • “Rituximab, what’s known, what isn’t”, May 2009 Newsletter, p. 5-7
  • Rituximab and immunity, March 2009 Newsletter, p. 15-16
  • Rituximab resistance and transformation, February 2010 Newsletter, p. 9-10
  • Chlorambucil and rituximab, June 2007 Newsletter, p. 9-10

Root Canals, May 2008 Newsletter, p. 7-8

Rosenberg, Dr. Saul

  • Dr. Rosenberg’s research and its implications for explaining spontaneous regression, February 2014 Newsletter, p. 2; 5-9
  • Dr. Rosenberg’s research on watch and wait, Article #5, p. 12-14; March 2008 Newsletter, p. 3-6; Article #2, 26-29

Roundup (Glyphosate)

  • Roundup and toxic exposure risks, May 2017 Newsletter, p. 5-7
  • Roundup weedkiller classified by the World Health Organization as a “probable carcinogen” linked to an increased risk of non-Hodgkin lymphoma, May 2015 Newsletter, p. 16-19

[ return to top ]

________________________________________________________

S

SAD (Seasonal Affective Disorder) , December 2015 Newsletter, p. 21-22 

Salmon (Wild), Article #3, p. 53

Salmon Oil (Wild)

  • Epigenetic anti-cancer effects of wild salmon oil, September 2015 Newsletter, p. 21-22; Article #11, p. 11
  • Article #3, p. 58

Scans

  • Vitamin E tocotrienols found to reduce damage from radiation scanning, Article #5, p. 32-33; July 2013 Newsletter, p. 19-22
  • PET scans and false positive results, Article #5, p. 30-31
  • Radiation dangers, May 2015 Newsletter, p. 12-16; April 2011 Newsletter, p. 7-10, January 2010 Newsletter, p. 14-17
  • “Caution re Eight or More CT Scans Plus PET”, May 2015 Newsletter, p. 12-16 (see correction to 4 or more scans in June 2015 Newsletter, p.17-19)
  • Treatment decisions and scans, Article #7, p. 9-10
  • Using MRIs and ultrasounds for routine scanning, Article #5, p. 31-32
  • Combined PET and CT scanning, May 2015 Newsletter, p. 12-16; Article #5, p. 30-31
  • Radiation exposure of CT scans, May 2015 Newsletter, p. 12-16; October 2009 Newsletter, p. 13-16; November 2007 Newsletter, p. 14-16; January 2006 Newsletter, p. 6-7
  • Recommendations for CT scan frequency, December 2013 Newsletter, p. 19-22; March 2009 Newsletter, p. 14
  • Secondary Cancers, May 2009 Newsletter, p. 12

Selenium

  • Epigenetic anti-cancer effects of selenium, Article #11, p. 14-15
  • Selenium as a daily supplement, Article #3, p. 58; March 2016 Newsletter, p. 19-21
  • Need to be taken with Vitamin E, Article #3, p. 50; November 2008 Newsletter, p. 9-10
  • Gene P53 and selenium, February 2013 Newsletter, p. 9-10; May 2011 Newsletter, p. 15-16, Article #3, p. 50; November 2008 Newsletter, p. 9
  • Brazil nuts and selenium supplements — actual selenium content, November 2008 Newsletter, p.9

Seyfried, Dr. Thomas, Article #11, p. 10; November 2012 Newsletter, p. 5-7

Sinus Congestion

  • Polysporin, bacitracin and sinus infection, December 2015 Newsletter, p. 23-24;  January 2012 Newsletter, p. 23
  • Mixing olive leaf extract in a saline solution for sinus congestion, May 2017 Newsletter, p. 19-20; February 2017 Newsletter, p. 19
  • Low IgA levels and chronic sinus infection, November 2011 Newsletter, p. 5
  • Managing nasal infection with polysporin, Article #3, p. 65
  • How to instructions for using steam vapors and essential oils to help clear sinus passages and prevent infection, December 2010 Newsletter, p. 16-18
  • Penetrating nasal passageways with tea tree oil and anise, November 2009 Newsletter, p.11-14
  • Adding oil of oregano to tea tree oil and anise oil mixture, February 2010 Newsletter, p. 16

Skin Conditions

  • Itchy skin and skin rashes, November 2010 Newsletter, p. 15-16
  • Staph infections and how to prevent them, June 2012 Newsletter, p. 22-23

Sleep

  • Epigenetic anti-cancer effects of quality sleep, Article #10, p. 19-21; Article #11, p. 14-15
  • Importance of quality sleep, May 2017 Newsletter, p. 20-21; December 2015 Newsletter, p. 26-27; August 2015 Newsletter, p. 19-21; June 2015 Newsletter, p. 11-13: January 2013 Newsletter, p. 16-17; Article #3, p. 33-39; March 2011 Newsletter, p. 21-22
  • “Sleep Deprivation Alters Genetic Expression …. Latest Research”, March 2013 Newsletter, p. 8
  • Bedtime snack doubles as a sleeping pill, December 2016 Newsletter, p. 19-20
  • Importance of totally dark room and sleep mask, Article #3, p. 35; June 2010 Newsletter, p. 17
  • Dietary fiber may help with sleep problems, March 2017 Newsletter, p. 11-13
  • Poor sleep linked to dietary fat and sugar, February 2016 Newsletter, p. 21-22
  • Quality sleep and chronic stress, Article #10, p. 19-20; Article #3, p. 33-39; February 2005 Newsletter, p. 10-11
  • Sleep and melatonin, Article #3, p. 30-32; September 2006 Newsletter, p. 11-12; March 2006 Newsletter, p. 9-12
  • Quality sleep, nighttime darkness, and breast cancer study, March 2008 Newsletter, p. 15-16
  • Sleep and the ROS (reactive oxygen species) cascade, Article #3, p. 37-38; November 2007 Newsletter, p. 9-11; June 2007 Newsletter, p. 16-17; December 2006 Newsletter, p. 9-11
  • Sleep and immunity, May 2005 Newsletter, p. 10-12
  • Natural technique for reinforcing the “hormone twins” (Vitamin D and melatonin) for a better night’s sleep, Article #3, p. 36; July 2008 Newsletter, p. 8-10

Spontaneous (Natural) Regression (SR)

  • Dr. Saul Rosenberg’s research on “watch and wait” and how it helps us understand spontaneous (natural) regression, February 2014 Newsletter, p. 5-9
  • Epigenetics, follicular lymphoma, and natural regression, Article #11, p. 21-22
  • “Updating What We Know About Spontaneous (Natural) Regression”, February 2014 Newsletter, p. 8-11
  • “Must know” details about SR for follicular patients, Article #10, p. 1-10; October 2009 Newsletter, p. 3-7; April 2006 Newsletter, p. 9-11
  • Frequent hiking in the sun and spontaneous regression, Article #10, p. 8-10; July 2013 Newsletter, p. 7-15
  • “A Real Life Example of an Epigenetic Intervention Leading to Spontaneous Regression”, Article #10, p. 8-10
  • Spontaneous regression as an indicator of long-term survival, March 2011 Newsletter, p. 20-21; August 2008 Newsletter, p. 17-18
  • Reactive oxygen species (ROS) cascade and spontaneous regression, November 2007 Newsletter, p. 9-11
  • Personal reflections on SR, October 2005 Newsletter, p. 2-4

Stages of Follicular Lymphoma, Article #5, p. 6-8; Article #2, p.16; Article #7, p. 7-8

STDs, December 2009 Newsletter, p. 17-18

Stem Cells

  • 2013 research explores the use of stem cells in a gene transfer method that targets tumor cells, November 2013 Newsletter, p. 16-17
  • Malignant stem cells, April 2007 Newsletter, p. 6-8; December 2006 Newsletter, p. 2-5

Stem Cell Transplants (SCTs)

  • Latest SCT research results (August 2013), September 2013 Newsletter, p. 13-17
  • SCTs and transformation, Article #4, p. 12; 20-22
  • Comparative data on relative effectiveness of chemotherapy, auto SCTs and allo SCTs in treating transformation in fNHL patients, April 2013, p. 17-20
  • New research on rituximab resistance and SCT outcomes, June 2014 Newsletter, p. 15-17
  • General information, Article #6, p. 21-24; Article #7, p. 29-31; August 2012 Newsletter, p. 17-18
  • Latest research on stem cell transplants and fNHL, including overall survival findings and key information on genetic factors, March 2013 Newsletter, p. 8-13
  • Study shows patients with pre-transplant deficient levels of Vitamin D have a much greater risk of developing graft vs. host disease in allogenetic stem cell transplants, October 2012 Newsletter, p. 14-17
  • New genetic research regarding diffuse components in transformation and relevance to an SCT, November 2011 Newsletter, p. 10-11
  • Autologous SCTs and the presence of the c-Myc gene in pathology reports, October 2011 Newsletter, p. 9-11
  • Web link to Greg Dafoe’s website Non-Hodgkin’s Lymphoma Cyberfamily,for high quality research and insights on fNHL and SCTs, January 2008 Newsletter, p. 9
  • Graft vs. host disease (GVHD) and SCTs, January 2008 Newsletter, p. 10-12
  • Mortality following an autologous SCT, August 2009 Newsletter, p. 11-12
  • Relapse after an autologous SCT, March 2009 Newsletter, p. 14-15
  • Mozobil and autologous SCTs, March 2009 Newsletter, p.15; August 2007 Newsletter, p. 6-7
  • SCT mortality statistics, January 2009 Newsletter, p. 7-8
  • Autologous SCTs and in-vivo purging, April 2008 Newsletter, p. 8-9
  • Autologous SCTs and prognostic indicators for long-term survival, February 2008 Newsletter, p.15
  • Second malignancies and SCTs, April 2005 Newsletter, p. 10-12
  • Harvesting stem cells, March 2008 Newsletter, p. 8-9
  • SCTs and older patients, July 2008 Newsletter, p. 13
  • Autologous SCTs and fNHL grade, November 2007 Newsletter, p. 18
  • Studies on long-term effectiveness of autologous SCTs, August 2007 Newsletter, p. 5-6; October 2006 Newsletter, p.17-20; March 2005 Newsletter, p. 8-11
  • Chlorambucil and SCTs, April 2007 Newsletter, p. 6
  • Harvesting healthy stems cells, December 2006 Newsletter, p. 5-7
  • Allogeneic SCTs, January 2005 Newsletter, p. 6-8

Steroids, January 2009 Newsletter, p. 10-11

Stress

  • “How Stress is Associated with Follicular Lymphoma”, December 2014 Newsletter, p. 17-23
  • Potentially harmful epigenetic effects of stress for cancer patients, Article #10, p. 21-22; Article #11, p. 15-16; October 2016 Newsletter, p. 22
  • Cortisol, stress and cancer, Article #10, p. 21-22; Article #11, p. 15-16; Article #3, p.37
  • Dietary fiber may help with stress problems, March 2017 Newsletter, p. 11-13
  • Stress, anxiety, psilocybin and cancer patients, January 2017 Newsletter, p. 10-11
  • April 2012 Newsletter, p. 14-16; Article #3, p. 32-33; June 2007 Newsletter, p. 15-16; December 2005 Newsletter, p. 7-8
  • “Medical Aspects of Stress and Cancer”, April 2013 Newsletter, p. 22-24
  • Stress and sleep, Article #3, p.38-42; July 2010 Newsletter, p. 10-13

Sulforaphane

  • Epigenetic anticancer effects of sulforaphane, Article #10, p. 24-25; Article #11, p. 16
  • Sulforaphane in broccoli, broccoli sprouts, and Brussels sprouts, a natural histone deacetylase (HDAC) inhibitor, February 2013 Newsletter, p. 5-6; April 2015 Newsletter, p.16-17; April 2012 Newsletter, p. 12-13; July 2011 Newsletter, p. 6-10; November 2010 Newsletter, p. 8-9

Sugar

  • “Sugar, Glutamine, and Cancer Genes”, April 2013 Newsletter, p. 3-7
  • Dietary challenges in reducing sugar in the diet, October 2014 Newsletter, p. 13-15; January 2013 Newsletter, p. 5-9
  • Research demonstrates sugar and glutamine intakes are inter-dependent in fueling cancer cell growth, February 2012 Newsletter, p. 3-8
  • Sugar as risk factor for cancer, Article #10, p. 22-24; Article #11, p. 10-11; Article # 3, p. 27-28; March 2012 Newsletter, p. 4-6; February 2011 Newsletter, p. 17; January 2010 Newsletter, p.19-20
  • Exercise as a strategy for reducing negative impact of sugar, Article #7, p. 36-37; Article #3, p. 32
  • Akt cell signaling pathway, sugar, and cancer, June 2008 Newsletter, p. 6-7
  • NF-Kappa B pathway, high sugar intake, and inflammation, February 2008 Newsletter, p.7

Sun exposure (incidence of fNHL), Article #10, p. 15; April 2007 Newsletter, p. 3-4

Sunlight

  • Sunlight activates FOXP3+ Treg cells crucial to long-term survival with fNHL, June 2017 Newsletter, p. 3-6; 10-12
  • Sunlight may be the most potent source of vitamin D, Article #10, p.14-16; Article #11, p. 18
  • New research reveals natural blue light in sunlight mobilizes anticancer activity in T cells, February 2017 Newsletter, p. 14-16
  • Residing in latitudes north of 55 degrees N associated with shorter overall survival time for lymphoma survivors, Article #10, p.15; November 2013 Newsletter, p. 15-16
  • MIT scientist proposes dietary sulphur intake and sunlight exposure are essential keys to optimal health, November 2011 Newsletter, p. 19-20
  • Breast cancer researchers find a combination of both sunlight and supplemental vitamin D is most effective in reducing cancer risk, Article 10, p. 15; March 2013 Newsletter, p. 17-18

Supplement Use

  • Avoiding the common error of over supplementation, August 2014 Newsletter, p. 19
  • Study finds excessive use of dietary supplements associated with increased cancer risk, May 2015 Newsletter, p. 20-21
  • Misuse of supplements can be toxic, Article #7, p. 13-17; March 2014 Newsletter, p. 17-18
  • Discussion of wise and unwise use of supplements and pitfalls of promotional diets, Article #7, p. 13-17; November 2011 Newsletter, p. 5-10
  • Dangers of over-using antioxidant supplements, Article #7, p. 13-17; December 2009 Newsletter, p.18-19; November 2009 Newsletter, p.15-16; July 2009 Newsletter, p.12-14; May 2008 Newsletter, p.12-13
  • Norwegian clinical trial investigates effects of supplementation for fNHL patients with omega 3 fatty acids (fish oil), selenium, garlic, ellagic acid (pomegranate juice), resveratrol/quercetin, green tea, June 2007 Newsletter, p. 16

Survival (see Long-Term Survival)

[ return to top ]

________________________________

T

T-Cell Immunotherapy

  • Breakthrough natural strategies to enhance T cell effectiveness, June 2017 Newsletter (entire)
  • February 2017 Newsletter, p. 11-13: June 2005 Newsletter, p. 1-3

Targeted Natural Strategies (4P-GRS) for Long-Term Survival (see also Lifestyle Strategies)

  • Detailed analysis and research guides to the epigenetic anticancer effects of the 4P-GRS  strategies suggested in Article #3: Article #10, Article #11
  • Ringleader fNHL genes and enzymes and targeted natural strategies affecting their epigenetic expression, February 2013 Newsletter, p. 2-25
  • High tumor microenvironment expression of CD7 and dietary lifestyle factors in fNHL patients linked to increased survival time, December 2012 Newsletter, p. 8-10
  • “Living the Natural Strategies Everyday”, August 2011 Newsletter, p. 3-11
  • Scientific premises for TNS, Article # 10, p. 9-13; Article #3, p.7-14; Article #11, p. 2-5; 20-24
  • The many advantages of using natural strategies to slow cancer progression, Article #10, p. 1-10
  • Updated dietary and supplementation strategies, Article #3, p. 42-60; October 2010 Newsletter, p. 8-19
  • Importance of Targeted Natural Strategies, March 2007 Newsletter, p. 4-11
  • “Jill’s Quick Action Plan”, suggestions to help get quickly “up and running” with 4 pillar lifestyle program presented in Article #3, September 2013 Newsletter, p. 23-24
  • Essence of Targeted Natural Strategies (the A Team), March 2008 Newsletter, p. 6-8
  • Controversy concerning the use of TNS and fNHL, October 2006, p. 3-8
  • Importance of the “before and after” strategies, Article #10, p. 6-7; August 2013 Newsletter, p. 16-18

Telomerase

  • Telomerase, telomeres, and cancer cells, June 2007 Newsletter, p. 8-9
  • Telomerase key to developing potential cancer breakthrough, March 2010 Newsletter, p.6

Tempo, Discussion of tempo and the “tipping point”, Article #6, p. 9-10

Toxoplasmosis, July 2006 Newsletter, p. 7-8

Toxins,  Article #11, p. 6-7,  May 2017 Newsletter, p. 4-15; September 2016 Newsletter, p. 4-12October 2013 Newsletter, p. 10-13

TP53 Gene

  • The potency of gene TP53 in influencing follicular lymphoma progression, November 2015 Newsletter, p. 18-20

Transformation

  • Essential information on follicular lymphoma transformation: Article #4
  • “Follicular Lymphoma Transformation — Past, Present and Future (latest research), January 2017 Newsletter, p. 5-9
  • “Latest Genetic Data Predicts Follicular Lymphoma Transformation”,  September 2016 Newsletter, p. 20-22
  • Important updated information on follicular lymphoma transformation, February 2015 Newsletter, p. 11-18
  • SUV uptake values and transformation, February 2015 Newsletter, p. 14-15
  • Interpretation of diffuse pattern results in tissue biopsies as it pertains to diagnosing transformation, Article #5, p. 17-19; Article #7, p. 20-24; September 2011 Newsletter, p. 17-18
  • Genes associated with follicular lymphoma transformation, Article #4, p. 19-20; June 2014 Newsletter, p. 4-8
  • Biopsies and uncertainty re interpretation of pathology results at the time of suspected transformation, Article #4, p. 6-8; Article #5, p. 17-19
  • Have I transformed?, Article #4, p. 6-8; Article #7, p. 20-24, March 2014 Newsletter, p. 4-7, July 2007 Newletter, p. 11-14
  • Research identifies specific genes associated with transformation, Article #4, p. 19-20; March 2014 Newsletter, p. 7-8
  • New chemo treatment R-GCVP developed for patients with heart concerns, Article #4, p. 10-11; March 2014 Newsletter, p. 8-9
  • “Localized” transformation and treatment options, Article #5, p. 17-19; Article #7, p. 22-23
  • Chemotherapy and transformation, Article #4, p. 8-12; September 2010 Newsletter, p. 3-6
  • Understanding transformation, Article #2, p. 33-36; Article #4, p. 1-9; Article #6, p. 5-8; Article #7, p. 20-24; November 2009 Newsletter, p. 5-9; February 2006 Newsletter, p. 2-9
  • Rosenberg, Dr. Saul, “Follicular Lymphoma Re-Visited”, March 2008 Newsletter, p. 3-6
  • Planning for transformation: most important considerations, Article #6, p.5-8
  • Critical information on possible shortage of chemotherapy drugs used to treat transformation, December 2010 Newsletter, p. 15-16
  • Major treatment options for transformation, Article #4, p. 8-12
  • Elevated LDH and transformation, Article #4, p. 5-6
  • Role of gene P53 in transformation, Article #4, p. 24; January 2008 Newsletter, p. 13-14
  • Risk of transformation rises 3% per year, November 2008 Newsletter, p.10-11
  • Natural strategies to combat transformation, Article #4, p. 24; November 2008 Newsletter, p. 12-13
  • Resveratrol and transformation, Article #4, p. 24
  • R-CHOP and transformation, Article #7, p. 19-25; Article #4, p.8-9
  • Web link to Dr. Zelenetz webcast on transformation, January 2011 Newsletter, p. 20
  • PET scans and transformation, Article #4, p.6-7
  • “Transformation: A Yes or No Event?”, March 2010 Newsletter, p. 9-11
  • B Symptoms and transformation, Article #4, p. 5-6; Article #2, p. 34: Article #3, p. 69-70
  • Treatments for second transformation, Article #4, p. 9-10; Article #6, p.26, Article #7, p.23-24
  • Biomarkers, predicting overall survival time,and transformation, Article #4, p. 15-16; September 2008 Newsletter, p. 5-6
  • Rituximab resistance and transformation, February 2010 Newsletter, p. 9-10
  • Research study on resveratrol and transformed fNHL cells, June 2009 Newsletter, p. 11-12
  • Prognostic indicators and transformation, Article #4, p. 15-16; November 2006 Newsletter, p. 9-12
  • Overall survival and transformation, Article #4, p. 13-15

Treatment-Wellness Spectrum, August 2012 Newsletter, p. 4-5; April 2011 Newsletter, p. 3-4, March 2010 Newsletter, p. 15-16: August 2008 Newsletter, p. 3-5; February 2010 Newsletter, p. 17

Triphala, June 2008 Newsletter, p.10

Tumor Suppressor Genes

  • The importance of tumor suppressor genes in holding fNHL in check, May 2016 Newsletter, p. 15-20; August 2015 Newsletter, p. 9-10; 21-23
  • Description of tumor suppressor genes, December 2016 Newsletter, p. 3-4: August 2015 Newsletter, p. 8-10
  • Animal research finds reactivation of key tumor suppressor gene can revert cancer cells to normal tissue, July 2015 Newsletter, p. 17-18
  • The importance of tumor suppressor genes in both fNHL growth and natural regression, May 2016 Newsletter, p. 15-20; August 2015 Newsletter (entire)

Turmeric (see curcumin)

Tyrosine Kinase Inhibitors

  • Natural inhibitors of tyrosine kinases, Article #11, p. 13
  • “Clinical Trial Results with New Kinase Drugs Idelalisib and Imbruvica”, January 2014 Newsletter, p. 12-16
  • Ibrutinib, BTK gene, concerns with immunity, September 2013 Newsletter, p. 3-13

[ return to top ]

__________________________________________________________

U

[ return to top ]

_____________________________________________________________

V

Vaccines

  • Biovax vaccine, August 2012 Newsletter, p. 7-8; August 2009 Newsletter, p.12-13; July 2008 Newsletter, p.14-17; January 2008 Newsletter, p. 5-6; December 2007 Newsletter, p.15-16
  • Vaccine novelty, July 2008 Newsletter, p.14-17
  • Why cancer vaccines may not work, June 2009 Newsletter, p.17-18; February 2009 Newsletter, p.12; January 2008 Newsletter, p.4-5; May 2005 Newsletter, p. 4-7
  • Bendandi vaccine, September 2008 Newsletter, p.16; March 2008 Newsletter, p. 9-10; January 2008 Newsletter, p.6; May 2007 Newsletter, p.2; January 2007 Newsletter, p. 2-5
  • Favrille vaccine, June 2008 Newsletter, p.11-12; January 2008 Newsletter, p.5 ; December 2007 Newsletter, p.15
  • MyVax vaccine, January 2008 Newsletter, p.2-4; December 2007 Newsletter, p.14-15
  • Common terminology used in discussing vaccine therapy, May 2005 Newsletter, p 6-7

Valporic Acid, July 2013 Newsletter, p. 22-23

Vascularization

  • Vascularization and fNHL, December 2007 Newsletter, p. 8-9
  • Research identifying vascularization as a strong prognostic indicator in regard to transformation and overall survival in fNHL, September 2010 Newsletter, p. 13-14
  • Ellagic acid and vascularization, Article #11, p. 7; Article #10, p. 25-26; September 2010 Newsletter, p. 14

Vegetable intake and lymphoma, July 2006 Newsletter, p. 6-7

Vitamin A,  October 2016 Newsletter, p. 16-20; Article #11, p. 14; December 2015 Newsletter, p. 14-18; April 2015 Newsletter, p. 14-16, February 2016 Newsletter, p. 14-22.

Vitamin B Complex,  April 2017 Newsletter, p. 18-22February  2017 Newsletter, p. 17June 2016 Newsletter, p. 7-12 ; Article #3, p. 58

Vitamin B-12, July 2009 Newsletter, p. 15-16

Vitamin D

  • Epigenetic anticancer effects of vitamin D, Article #10, p.13-16; Article #11, p. 18
  • The vital necessity of vitamin D for follicular lymphoma survivors, May 2016 Newsletter, p. 20-24, Article #3, p.19-24
  • 2016 research finds insufficient vitamin D levels are directly linked to higher relapse rates and inferior overall survival in follicular lymphoma survivors, July 2016 Newsletter, p. 10-15
  • Not optimizing vitamin D is a strategic error for fNHL patients, April 2015 Newsletter, p. 18-20
  • Low vitamin D levels in fNHL patients found to be “surprisingly strong” prognostic indicators for overall survival (OS) outcomes, May 2015 Newsletter, p. 4-6; Article #10, p. 14; December 2012 Newsletter, p. 6-8
  • Vitamin D and intestinal health, October 2016 Newsletter, p. 9-10
  • “The Sensible Management of Vitamin D”, November 2011 Newsletter, p. 13-16
  • Epigenetics, follicular lymphoma, natural regression, and the Myc gene, Article #11, p. 18-19
  • Ensuring a year-round optimum level of Vitamin D, Article #7, p. 11-13; Article #3, p. 19-24
  • Using vitamin D as a prognostic indicator of survival, Article #2, p. 29-31
  • Vitamin D testing information, July 2016 Newsletter, p. 15; April 2011 Newsletter, p. 21, Article #3, p.23
  • Clinical research studies on cancer and Vitamin D levels
    • Vitamin D follicular lymphoma study reports low serum vitamin D levels associated with inferior overall survival, July 2016 Newsletter, p. 10-15; May 2015 Newsletter, p. 4-6
    • Summary of 2012 vitamin D research study from Norway, “best yet” for associations with overall survival in lymphoma patients, April 2013, p. 10-12
    • Vitamin D found to inhibit the production and function of protein cMyc, which helps to drive cancer cell division, February 2013 Newsletter, p. 6-8
    • Breast cancer researchers find a combination of both sunlight and supplemental vitamin D is most effective in reducing cancer risk, March 2013 Newsletter, p.17-18
    • “Summarizing the latest research”, February 2012 Newsletter, p. 10-18
    • Cancer patients have lower vitamin D levels, January 2012 Newsletter, p. 10-13
    • Clinical trial results show insufficient Vitamin D levels in CLL patients linked to cancer progression and survival times, December 2010 Newsletter, p. 9
    • Research shows vitamin D levels declining in general population, March 2012 Newsletter, p. 13-14
    • Study finds pre-transplant deficient levels of Vitamin D have a negative impact on outcomes of allogenetic stem cell transplants, October 2012 Newsletter, p. 14-17
    • December 2009 Newsletter, p.13-15
    • New model of cancer development cites low Vitamin D, June 2009 Newsletter, p. 9-10
    • Vitamin D and depression, October 2008 Newsletter, p.12
    • Breast cancer and low levels of Vitamin D, June 2008 Newsletter, p. 5-6
    • Mayo Clinic 2010 research on Vitamin D and fNHL, September 2010 Newsletter, p. 14-16
  • Vitamin D supplements and dosage considerations, February 2012 Newsletter, p. 10-18; October 2009 Newsletter, p. 7-9
  • Researchers attempt to define optimal vitamin D level, September 2012 Newsletter, p.15-16
  • Barriers in achieving optimal Vitamin D levels, June 2009 Newsletter, p. 4-9; May 2008 Newsletter, p. 6-9
  • Fat solubility and supplementation, Article #3, p. 20,41
  • “Vitamin D and Immunity: A Double-Edged Sword”, May 2010 Newsletter, p. 7-9
  • Vitamin A may limit optimization of Vitamin D, March 2010 Newsletter, p. 14-15
  • Vitamin D and sunlamps, Article #3, p.24
  • Vitamin D and sunscreen, June 2010 Newsletter, p. 18
  • Vitamin D and bathing, February 2010 Newsletter, p. 14
  • Personal comments from Dr. Gabe Mirkin, May 2009 Newsletter, p. 13-14; May 2008 Newsletter, p. 2-6, September 2010 Newsletter, p. 16

Vitamin E

  • Epigenetic anti-cancer effects of tocotrienols in vitamin E, Article #11, p.17
  • “Vital Role of Full Spectrum Vitamin E”, March 2011 Newsletter, p. 12-13
  • Vitamin E tocotrienols found to reduce damage from radiation scanning, July 2013 Newsletter, p. 19-22
  • Why the 2014 SELECT research results are compromised by use of synthetic vitamin E, March 2014 Newsletter, p. 16-18
  • Vitamin E tocotrienols anti-cancer benefits, April 2009 Newsletter, p. 12-14
  • Rice bran oil as source of tocotrienol component of Vitamin E, March 2011 Newsletter, p. 12-13
  • Red palm oil as a full-spectrum source of Vitamin E, Article #7, p. 47; May 2011 Newsletter, p. 42-44, March 2011 Newsletter, p. 12-13; Article #3, p. 50-51; April 2009 Newsletter, p. 12-14
  • Vitamin E needs to be taken with selenium, Article #3, p. 50
  • Vitamin E and NF-Kappa B pathway, January 2008 Newsletter, p. 17-18

Vitamin K

  • “Vitamin K2 Must Accompany Vitamin D: Here’s Why”, January 2014 Newsletter, p. 18-21
  • Epigenetic anti-cancer effects of vitamin K-2, Article #11, p.19
  • The importance of K-2 (menaquinone) and how to get it from dietary sources, March 2013 Newsletter, p. 18-20; February 2012 Newsletter, p. 25-27; Article #3, p. 57; November 2011 Newsletter, p. 20; September 2011 Newsletter, p. 18-19
  • Mayo Clinic research study, April 2010, May 2010 Newsletter, p. 13-14

Vorinostat, Article #6, p. 31-32; August 2012 Newsletter, p. 18-19

[ return to top ]

________________________________________________________

W

Walnuts, February 2012 Newsletter, p. 25; April 2011 Newsletter, p. 23

Warburg, Dr. Otto

  • Summary description of the “Warburg Effect” and its importance in getting follicular lymphoma cells to die on their own, Article #10, p. 6-7
  • Dr. Warburg’s contributions to understanding cancer causation, June 2010 Newsletter, p. 3-6
  • Dr. Warburg’s theory about cancer and lack of effective mitochondrial function in cancer cells, Article #10, p. 12-14; November 2010 Newsletter, p.10

Watch and wait (see Dynamic Observation)

Weil, Dr. Andrew, March 2008 Newsletter, p. 17-18, May 2010 Newsletter, p. 17

Wheatgrass, February 2013 Newsletter, p. 16-17

Whey Protein

  • Whey protein powders should be avoided by fNHL patients, Article #10, p. 26-27; June 2013 Newsletter, p. 13-14: Article #7, p. 43-44; December 2012 Newsletter, p. 12-13; June 2012 Newsletter, p. 17-19; Article #3, p. 55

Will to Live, Article #3, p. 68-69; April 2010 Newsletter, p. 21

[ return to top ]

________________________________________________________

X

[ return to top ]

________________________________________________________

Y

Yogurt

  • Article #3, p. 57; April 2015 Newsletter, p. 21-23
  • Fermented milk products a healthier choice than milk, June 2016 Newsletter, p. 13-15;  May 2015 Newsletter, p. 22-23
  • “Six Reasons Why Yogurt is Essential”, March 2015 Newsletter, p. 17-19
  • Yogurt as source for probiotics and calcium, October 2016 Newsletter, p. 9; Article #11, p.12
  • Yogurt boosts the brain, December 2016 Newsletter, p. 8-11
  • Information on making homemade yogurt, October 2013 Newsletter, p. 16-18

[ return to top ]

________________________________________________________

Z

Zevalin

  • General information, Article #6, p.24; August 2012 Newsletter, p. 19-20
  • Zevalin manufacturer requests removal of pre-treatment evaluation bioscan, February 2011 Newsletter, p. 13-14
  • Significance of FDA approval, September 2009 Newsletter, p. 2-6
  • Research comparing Zevalin and Bexxar, July 2008 Newsletter, p. 13-14
  • 2008 Italian research study, April 2008 Newsletter, p. 7-8
  • Research evaluating effectiveness, June 2010 Newsletter, p.12-13

Zinc, Article #3, p.48

[ return to top ]